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Abstract: The world of molecular profiling has undergone revolutionary changes over  
the last few years as knowledge, technology, and even standard clinical practice have  
evolved. Broad molecular profiling is now nearly essential for all patients with meta-
static solid tumors. New agents have been approved based on molecular testing 
instead of tumor site of origin. Molecular profiling methodologies have likewise 
changed such that tests that were performed on patients a few years ago are no 
longer complete and possibly inaccurate today. As with all rapid change, medical 
providers can quickly fall behind or struggle to find up-to-date sources to ensure he 
or she provides optimum care. In this review, the authors provide the current state 
of the art for molecular profiling/precision medicine, practice standards, and a view 
into the future ahead. CA Cancer J Clin 2019;69:305-343. © 2019 The Authors. CA 
A Cancer Journal for Clinicians published by Wiley Periodicals, Inc. on behalf of 
American Cancer Society. This is an open access article under the terms of the 
Creative Commons Attribution-NonCommercial License, which permits use, dis-
tribution and reproduction in any medium, provided the original work is properly 
cited and is not used for commercial purposes.
Keywords: biomarkers, cancer, gene expression profiling, drug target, molecular-
targeted therapy, molecular profiling, mutation, precision medicine, sequence analysis
Molecular Testing and Its Evolution
Comprehensive molecular profiling of patient tumors has been widely studied over 
the last few years in a variety of cancers, leading to the development of a new 
discipline termed “personalized” or “precision” medicine. Molecular profiling is 
becoming standard practice for most patients with advanced disease, replacing the 
historical treatment paradigm of prescribing standard chemotherapy based upon 
the tumor’s organ of origin, histology, and stage. This approach has allowed oncol-
ogists to reorganize the way they think about cancer and to make treatment recom-
mendations based upon genomic drivers of tumorigenesis. In some cases, this has 
produced dramatic, positive outcomes, including complete remissions, even in the 
setting of treatment-refractory disease, delighting both patients and their caregivers.
The molecular profiling field is evolving rapidly. We are now shifting our 
focus from a few small, predictive, disease-specific, evidence-based tests—chosen 
“a la carte”—to broader panel testing that measures levels of or changes in myriad 
“genes or gene products.” These genomic changes can serve as biomarkers of both 
response prediction (indicating tumor and patient outcome/response to a specific 
therapy) and a patient’s prognosis (describing innate tumor aggressiveness, which 
aligns with patient survival regardless of treatment received). Increasing num-
bers of biomarkers have been identified for which targeted drugs are being dis-
covered and exploited therapeutically. Scientific advances go hand-in-hand with 
technological advances, which lead to improved therapeutic choices, all of which 
have garnered US Food and Drug Administration (FDA), Centers for Medicare & 
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Medicaid Services (CMS), and insurance company attention. 
Growing acceptance of evidence-based biomarker testing 
for the purpose of targeting treatment to solid tumors has 
ensued. Notably, Foundation Medicine’s FoundationOne 
CDx assay, which tests for several well-known markers using 
next-generation sequencing (discussed later in this review), 
was recently approved by the FDA and concurrently accepted 
by the CMS.1,2
To facilitate cancer therapy, it is important to distinguish 
between germline abnormalities and somatic abnormalities. 
A very good example of this is the recently incorporated 
BReast CAncer gene (BRCA) germline testing for all pa-
tients with pancreatic cancer. Germline testing involves an 
extensive coverage of BRCA, whereas current somatic test-
ing covers only certain regions of that gene. As mutation 
analysis evolves into whole exome sequencing, coverage of 
germline and somatic testing will be similar if not identical. 
Given the increased need for somatic testing in patients with 
pancreatic cancer, it is possible that whole exome sequenc-
ing will replace germline testing in guidelines to come. As 
these “standard” tests evolve, they make the choices facing 
patients and providers more complex while providing hope 
that harnessing this knowledge will translate into substantial 
benefits for patients, including cancer cures and prevention.
Molecular Profiling and Its Methodology
Molecular profiling refers to the assessment of DNA, RNA, 
and/or proteins within an individual patient’s cancer using 
cells obtained from a tumor biopsy or through the capture 
of tumor cells circulating in the bloodstream, with the lat-
ter being less well established as a methodology. The term 
“molecular profiling” was initially applied to DNA analysis 
but evolved with advances in technology to take on a broader 
meaning to encompass analyses of RNA and proteins. 
DNA-level alterations do not necessarily lead to biological 
alterations, thus making examination at the “multiomic” 
(transcriptome and proteome) level imperative. This multi-
pronged analysis results in the generation of an inordinate 
amount of data that can be processed only with the help of 
bioinformatic methodology. Bioinformaticians combine a 
host of scientific and mathematical data to create a computer 
infrastructure that assists in the analysis and interpretation 
of biological data and picks out correlations between certain 
gene mutations and response to a specific therapy.3 Currently 
used molecular profiling techniques are as follows:
DNA and RNA
• Polymerase chain reaction (PCR) is used to amplify and 
detect DNA and RNA sequences. Standard PCR involves 
the amplification of one or more copies of a chosen DNA 
sequence to produce millions of copies and enable detec-
tion and analysis. Reverse transcription PCR converts 
RNA templates into complementary DNA for molecular 
analysis.
• In situ hybridization (ISH) localizes and determines 
a specific DNA or RNA sequence in a tissue section 
(in situ) or in circulating tumor cells using a labeled com-
plementary DNA, RNA, or modified nucleic acid strand 
probe. This technique detects gene deletions, amplifi-
cations, translocations, and fusions. Gene fusions com-
monly occur in epithelial cancers as a result of genomic 
rearrangements or abnormal mRNA processing. ISH 
techniques include chromogenic ISH and f luorescence in 
situ hybridization (FISH).
Chromogenic in situ hybridization (CISH) uses brightfield 
microscopes for label detection.
FISH uses f luorescence microscopes for label detection.
• Sanger sequencing examines strands of DNA to identify 
mutations by analyzing long, contiguous sequencing 
reads. This DNA sequencing takes place according to the 
selective incorporation of chain-terminating dideoxynu-
cleotides by DNA polymerase during in vitro DNA rep-
lication. This was the primary sequencing method used 
for well over 20 years and, although it is still widely used, 
next-generation sequencing (NGS) is now preferred for 
multigene/variant assessment.
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• NGS is a high-throughput technique that rapidly examines 
and more broadly detects DNA mutations (often used for 
circulating tumor DNA), copy number variations (CNVs), 
and gene fusions (using an RNA sequencing panel) across 
the genome. NGS can be performed on a range of cancer 
types using blood, solid tissue, and bone marrow samples. 
Precise tissue collection and workup are necessary for accu-
rate results. Laboratory regulatory agencies constantly pro-
vide updated guidance documents pertaining to the design, 
development, and use of NGS-based tests, recognizing the 
importance of NGS in cancer diagnostics and therapeutics.
• Pyrosequencing detects and quantifies mutations, methyl-
ation, etc, through sequencing by synthesis—a method 
that performs DNA sequencing by detecting the nucleo-
tide that is incorporated by DNA polymerase.
• Fragment analysis detects changes in DNA (eg, the length 
of a specific DNA sequence) or RNA to indicate the pres-
ence or absence of an inserted or deleted genomic sequence.
Protein
• Immunohistochemistry (IHC) uses the principles of anti-
body binding to proteins to determine the levels of pro-
tein expression in tissue samples. Tumor-related proteins 
of interest can include tumor-specific antigens, protein 
products of oncogenes and tumor suppressor genes, tumor 
cell proliferation markers, and enzymes.
Molecular Profiling Assays and Why Physician 
Oncologists and Pathologists Should Be Familiar 
With Them
Modern approaches to tumor profiling assess DNA, RNA, 
and proteins to form a detailed molecular map to guide more 
precise and individualized treatment decisions. Because the 
field of molecular profiling is continually evolving, physician 
education is vital. Clinical oncologists and pathologists bene-
fit greatly from an understanding of the technology involved, 
possibly even gaining hands-on experience in molecular pro-
filing assays and their interpretation. Any treating physician 
should know what, when, and how to test and how to make 
subsequent informed, patient-personalized treatment deci-
sions.4,5 Correct interpretation of profiling results is critical; 
many fear that overinterpretation or misinterpretation will 
lead to treatment of patients with ineffective but expensive 
therapies, negatively affecting not only patient lives but also 
the health care budget. Laboratories offering broad molecu-
lar profiling services should be suitably Clinical Laboratory 
Improvement Amendments (CLIA)–certified for this exact 
purpose to ensure quality control (see CLIA-approved labo-
ratories offering molecular panel analysis, below). However, 
even CLIA-certified laboratories do not use identical meth-
odologies and techniques, which can still lead to variable 
results. Reproducibility is key, and the rationale behind assay 
cutoff limits should be strong. Even before a patient sam-
ple is submitted for profiling, the pathologist or the treat-
ing physician—whoever plays the lead role in any particular 
institution—must ensure quality-controlled tissue sample 
collection.6,7 Reputable molecular testing laboratories will 
advise on the exact set of tumor profiling tests to perform, 
how to process samples, and how to interpret the final gen-
erated report, which is created to inform physicians of treat-
ment choices for their patients. Still, physician education is 
key to such a critical set of processes.
Biomarker Testing in the Clinic
Targeted therapies are showing efficacy in the right subgroups 
of patients. Of course, these subgroups must be defined, and 
this process is becoming more accurate and efficient with 
evolving molecular testing methods and broader use in 
research and in the clinic. As this process improves, treat-
ment options will improve for an increasing number of 
patients while eventually emerging as a more cost-effective, 
generally beneficial option compared with the currently 
accepted trial-and-error treatment model.
The biomarker information within Tables 1 through 2.12 is 
based mainly on the National Comprehensive Cancer Network 
(NCCN) Clinical Practice Guidelines in Oncology (NCCN 
Guidelines), NCCN Biomarkers Compendium (NCCN.org, 
Accessed February 6, 2019), and FDA recommendations and 
approvals (for the full definitions of all genes, please see the 
Supporting Information). Although the NCCN Biomarkers 
Compendium details not only predictive but also prognostic, 
diagnostic, screening, monitoring, and surveillance markers, the 
focus of this current review is on predictive biomarkers that can 
be used to guide treatment decisions. Within Tables 1 through 
2.12, the classifications in the “evidence” columns are based on 
the level of clinical evidence available and the degree of consensus 
among NCCN panel and other experts. In some cases, clinical 
evidence comes from large, well-designed, randomized 
controlled trials, but in many cases, it is mostly based on data 
from indirect comparisons among randomized trials, phase 2 
or nonrandomized trials, multiple smaller trials, retrospective 
studies, or merely clinical observations. In some cases, substan-
tial clinical data are lacking and evidence comes from clini-
cal experience alone. On the basis of all these factors and how 
compelling the data are, the evidence is rated as:
1. Based upon high-level evidence, there is uniform 
NCCN and other expert consensus that the intervention is 
appropriate (high-level, wide acceptance).
2A. Based upon lower level evidence, there is uniform 
NCCN and other expert consensus that the intervention is 
appropriate (lower level, wide acceptance).
2B. Based upon lower level evidence, there is some 
NCCN and other expert consensus that the intervention is 
appropriate (lower level, limited acceptance).
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Infrequent but Important Site-Agnostic Biomarkers
Microsatellite instability-high tumors and DNA mismatch 
repair
Microsatellite instability (MSI) is the result of inactiva-
tion of the DNA mismatch repair (MMR) system and is 
characterized by a high frequency of frameshift mutations 
in microsatellite DNA. In a portion of tumors, MSI is 
caused by germline mutations in one of the MMR genes 
(MLH1, MSH2, MSH6, or PMS2), which results in heredi-
tary Lynch syndrome. However, the majority (80%) of MSI 
cases are sporadic, often because of hypermethylation of the 
MLH1 gene promoter.8,9
MSI-high (MSI-H) has been found in as many as 
24 primary cancer types, most of which are displayed in 
Table 3,10,11 and appears to be a generalized cancer phe-
notype in about 4% of all adult cancers. Tumor MSI-H 
status is prognostic (patients with early-stage cancers that 
are MSI-H have a better prognosis than those with mi-
crosatellite stable tumors) as well as predictive—many 
MSI-H tumors are exquisitely sensitive to PD-1/PD-L1 
inhibitors.12,13
At present, the FDA has granted approval for practi-
tioners to administer the PD-1 inhibitor pembrolizumab 
for the treatment of patients with unresectable or meta-
static, MSI-H or MMR-deficient (dMMR) solid tumors 
(site-agnostic). Currently, the approval is for patients with 
tumors that have progressed after prior treatment who have 
no satisfactory alternative treatment options, as well as for 
patients with MSI-H or dMMR colorectal cancer (CRC) 
after progression on a f luoropyrimidine, oxaliplatin, and 
irinotecan, and in the first line for non–small cell lung can-
cer (NSCLC).14,15 In 2017, the FDA granted accelerated 
approval of single-agent nivolumab, another PD-1 inhibi-
tor, for the treatment of adult and pediatric patients older 
than 12 years with MSI-H or dMMR CRC. Subsequently, 
in 2018, the FDA granted accelerated approval to a combi-
nation of nivolumab plus ipilimumab (a CTLA-4 inhibitor) 
for treatment of the same set of patients.16,17 See Table 1 for 
MSI/MMR biomarker testing recommendations.
Neurotrophic receptor tyrosine kinase
Members of the neurotrophic receptor tyrosine kinase 
(NTRK) fusion oncogene family, NTRK1/NTRK2/
NTRK3, are most prevalent in rare adult cancer types and 
in several pediatric cancers, although they can occur in a 
very small proportion (approximately 1%) of commonly oc-
curring cancer types in adults, including NSCLCs, CRCs, 
head and neck cancers, thyroid cancers, bladder cancers, 
gliomas, and malignant melanomas (Table 418). NTRK1, 
NTRK2, and NTRK3 fusions and the proteins they en-
code (neurotrophin receptor kinase A [TRKA], TRKB, 
and TRKC, respectively) are observed at an increased fre-
quency in highly aggressive cancers such as glioblastoma TA
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multiforme, and recognition of their potential oncogenic 
activity led to the use of this fusion family as a predictive 
biomarker as well as a drug target.25
Larotrectinib is an oral and highly selective TRK in-
hibitor that was granted accelerated approval by the FDA 
on November 26, 2018, for the treatment of adult and 
pediatric patients with metastatic or unresectable solid 
tumors that have an NTRK fusion without a known 
acquired resistance mutation (NTRK kinase domain 
mutations, including solvent front mutations). Patients 
must have a cancer that has progressed after treatment 
and/or have no satisfactory alternative treatment for their 
 disease.26 The approval of larotrectinib is the second tissue- 
agnostic FDA approval, after pembrolizumab, for the 
treatment of cancer.
Another TRK inhibitor named entrectinib (RXDX-
101) was granted a breakthrough therapy designation by 
the FDA in 2017, although it has not yet been approved 
for use as a treatment for adult and pediatric patients who 
have NTRK-positive, locally advanced or metastatic solid 
tumors that have either progressed after prior therapies or 
have no acceptable standard therapy options.27,28
NTRK fusion testing has evolved massively over the 
last year or 2, and new discoveries are constantly being 
made using a range of different assays. The NTRK 
fusions displayed in Table 418 are taken from a study that 
was originally published in 2018. Although comprehen-
sive at the time, this table does not contain the complete 
list of fusions known today, in 2019. IHC has been used 
as an initial screening tool to inform highly sensitive but 
less available and more expensive molecular testing meth-
odologies.29-31 However, it is now clear that IHC does 
not have sufficient sensitivity to detect all existing NTRK 
fusion-encoded proteins, meaning that tumor samples 
should certainly be assayed using FISH or NGS from 
the get-go.18 In conclusion, clinicians need to be aware 
of all 3 TRK targets and arrange adequate testing for all 
of them.
Germline alterations and their testing
Gene mutations can be somatic or germline; the former 
spontaneously occur after birth, and the latter are inher-
ited (ie, present at birth). Tumor genetic (somatic) testing 
detects mutations that may actually be germline alterations, 
but germline alterations require confirmation in matched 
normal samples (eg, DNA extracted from white blood cells, 
buccal swabs, or cultured skin fibroblasts) from the tumor-
bearing host. Suspected germline mutations and genetic 
testing are relevant to cancer treatment and prevention. 
There is potential for patients to develop tumors at other 
TABLE 2.2. Currently Recommended Predictive Molecular Testing for Colon and Rectal Cancers
BIOMARKER
TEST 
DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
KRAS/NRASa Mutation Workup for 
metastatic 
disease 
(suspected or 
proven)
NGSb Avoid cetuximab or  
panitumumab treatment 
in patients who have 
tumors with KRAS and 
NRAS mutations (exons 
2, 3, and 4 in both)
NCCN indicate lower 
level, wide  
acceptance, but 
many believe  
classification is 
high-level, wide 
acceptance
Metastatic synchronous 
adenocarcinoma (any T, 
any N, M1),  
suspected or  
documented; or
Metachronous  
metastases by CT, MRI,  
and/or biopsy, 
documented
BRAFa Mutation 
V600E
Workup for 
metastatic 
disease 
(suspected or 
proven)
NGS, pyrosequenc-
ing, AS-PCRb
Cetuximab or panitu-
mumab treatment is not 
recommended in patients 
who have tumors with 
BRAF V600E mutations  
unless given with a BRAF  
inhibitor such as 
vemurafenib
The use of irinotecan in  
combination with 
cetuximab or panitu-
mumab plus vemurafenib 
is recommended in all 
patients with previously 
treated mCRC
NCCN indicates lower 
level, wide  
acceptance, but 
many believe  
classification is 
high-level, wide 
acceptance
Metastatic synchronous 
adenocarcinoma (any T, 
any N, M1),  
suspected or  
documented; or
Metachronous  
metastases by CT, MRI,  
and/or biopsy, 
documented
Abbreviations: AS-PCR, allele-specific polymerase chain reaction; CT, computed tomography; mCRC, metastatic colorectal cancer; MRI, magnetic resonance 
imaging; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; PCR, polymerase chain reaction.
aKRAS and NRAS are determined alongside BRAF mutations.
bTesting can be performed on primary and/or metastatic colorectal tissue specimens.
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sites or for family members to develop cancer, particularly 
early-onset malignancies.
Table 532 lists the somatic mutations that may be germ-
line. This table indicates the cancer types for which germ-
line testing should be carried out if the specified somatic 
mutations are found in a patient’s tumor profile.
There are 3 main categories of tumor genetic mod-
ifications with wide variation in the expectation that 
these ref lect germline changes. The first comprises 
common tumor mutations associated with rare germline 
alterations. For example, mutations in TP53 are found 
in greater than 60% of lung cancers.33 Although TP53  
mutations can be inherited in the Li-Fraumeni syndrome, 
such familial syndromes are rare. It is believed for the 
most part that there is little need for germline testing 
unless the personal or family history is suggestive of such 
a syndrome. The second category comprises moderately 
common somatic mutations that may be associated with 
familial syndromes. For example, in colon cancer, dMMR 
is found by routine MSI or IHC testing in about 12% 
of tumors.34 Molecular germline testing demonstrates 
that about one-quarter of these dMMR alterations are 
inherited. Hence tumor testing should lead to germline 
confirmation in patients and possibly further evaluation 
of family members. The final category comprises uncom-
mon tumor mutations that often ref lect germline muta-
tions. As an example, patients with breast and ovarian 
cancers regularly have germline testing done for BRCA1 
and BRCA2, especially if the personal or family history 
is suggestive. With routine molecular genetic tumor 
testing, BRCA1/BRCA2 mutations are being found in 
patients with other tumors where it is less expected. An 
analysis of 100 patients with pancreatic cancer found that 
7 had mutations in BRCA2, 4 of which were in the germ-
line.35 Finding BRCA1/BRCA2 mutations in the tumor 
may aid in choosing therapy but requires germline testing 
for confirmation and consideration of genetic counseling 
for the family.
It has generally been considered that germline testing is 
not always needed if somatic tumor testing has been done. 
However, it must be kept in mind that molecular genetic 
tumor testing can miss a small percentage of inherited 
cases, where mutations are outside the hotspots covered in 
the somatic panel or large-scale deletions and duplications 
have occurred. Conversely, larger gene panel profiling may 
actually identify previously unknown, clinically relevant 
alterations that are germline, either de novo or inherited 
from parents, despite a lack of associated clinical history.36
In conclusion, taking into consideration the increas-
ing availability of germline testing and whole exome 
sequencing to identify inheritable mutations, as well 
as the personal and family history of cancer and the 
potential need for genetic counseling, medical teams 
can help provide better treatment selection for patients 
with some types of cancer and help to create a systematic 
approach to hereditary risk.
Disease-Specific Biomarkers
In the subsections below and in Tables 2.1 through 2.12, we 
address the currently accepted genes or gene products that 
act as predictive biomarkers (and risk assessment markers in 
some cases) for each specific solid tumor. Details on when 
in the disease course the presence or levels of these mark-
ers should be assessed are also included. Under each of the 
following subsections, we also include some description of 
pertinent biomarkers in research. Compelling evidence sug-
gests that these biomarkers will be listed in the NCCN “rec-
ommended” biomarker category in the foreseeable future.
Lung cancers
Lung cancer therapy continues to follow the genomic 
testing paradigm (see Table 2.115,19-24). All patients with 
NSCLC should be tested for EGFR, ALK, ROS1, BRAF, 
and PD-L1 at baseline before treatment. Patients with 
uncommon mutations of EGFR may also be treated with 
tyrosine kinase inhibitor therapy. Other recommended 
markers of interest include EGFR insertion 20 mutations, 
RET rearrangements, and MET exon 14 mutations. All of 
these targets are still being actively investigated in clinical 
studies and hold potential for patient treatment.
Gastrointestinal cancers
Colon and rectal cancers. Oncologists now recommend the 
assessment of several predictive markers in patients with 
CRCs (see Table 2.2). The ideal time to perform genomic 
testing for treatment purposes is a matter of some controversy 
and varies depending on disease stage. At the time of initial 
diagnosis of a stage I, II, or III tumor, it is reasonable to 
perform MSI testing. Patients with MSI-H, locally confined 
tumors have a better prognosis, and recommendations 
are for patients with MSI-H stage II tumors to forgo 
 adjuvant therapy.37,38 Additional evidence suggests 
that 5-f luorouracil (5-FU) and related agents, such as 
capecitabine, can actually worsen outcomes when delivered 
as single agents to patients with early-stage MSI-H 
CRCs.39,40 Treatment with an oxaliplatin regimen is the 
standard of care recommended for MSI-H stage III CRCs. 
Finally, guidelines now recommend universal MSI testing 
in all stages of CRC to determine whether patients have a 
germline mutation indicative of Lynch syndrome.41 If both 
the tumor DNA and the patient’s germline DNA harbor 
an MMR defect, this indicates that the patient has Lynch 
syndrome. Oncologists need to refer these patients for 
 genetic counseling and a discussion about potential testing 
of relatives. Such individuals should have screening for 
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Lynch syndrome–associated cancers at an earlier age, and 
more intensive screening is called for than is recommended 
for individuals without such a cancer susceptibility 
mutation. There is additional evidence that the use of 
aspirin can reduce premalignant polyp formation in patients 
and their relatives with MSI-H tumors.43 Aspirin has also 
been associated with improved outcomes in patients with 
tumors that harbor PIK3CA mutations, suggesting a 
potential value for assessment of mutations in that gene.44 
MSI testing is also an eligibility requirement for the 
current US intergroup trial of combined 5-FU, leucovorin, 
and oxaliplatin (FOLFOX) with or without atezolizumab, 
a PD-1 inhibitor, in patients with MSI-H stage III colon 
cancer.
In patients with advanced CRC, MSI testing is also in-
dicated at diagnosis. Mutations in or overexpression of addi-
tional genes that are predictive of outcomes include BRAF, 
HER2, KRAS, NRAS, NTRK, POLE, PIK3CA, PTEN, 
and RSP03. Often, other than for RAS mutations, the opti-
mal time for this testing is when tumors become refractory 
to standard chemotherapy so that the assessment ref lects 
the current status of the disease. Patients with MSI-H 
tumors are now eligible for therapy with PD-1–targeting, 
PD-L1–targeting, and/or CTLA-4–targeting immuno-
therapies after their disease becomes refractory to standard 
chemotherapy. Those with NTRK fusions are candidates 
for treatment with larotrectinib.26 Individuals whose 
tumors harbor an RAS mutation are insensitive to treat-
ment with and should not receive an anti-EGFR–targeted 
monoclonal antibody such as cetuximab or panitumumab.45 
It is likely that additional genomic analyses that are cur-
rently underway or to be evaluated in future studies, involv-
ing whole genome or whole exome sequencing in cohorts of 
patients with known outcomes, will identify other muta-
tions that have either prognostic or predictive utility.
BRAF as a CRC prognostic factor. BRAF mutational status 
is used as a strong predictor for overall survival (OS) at all 
stages of disease; patients with BRAF-mutated CRC have 
a generally poor prognosis.46-52BRAF V600E is the best 
known mutation assessed using NGS.53 Compared with 
patients who have CRC with BRAF wild-type tumors, 
patients whose tumors manifest a BRAF mutation are 
generally older and more likely to be female. Such patients 
commonly have higher grade cancers at diagnosis, with 
a primary tumor that is more likely to be right-sided and 
to have a higher number of cancer-involved lymph nodes. 
These BRAF-mutated tumors are also more likely to be 
MSI-H.54
Gastric, esophageal, and gastroesophageal junction 
cancers. See Table 2.3.42
Pancreatic cancers. See Table 2.4.
Genitourinary cancers
Bladder cancers. In The Cancer Genome Atlas extended 
2017 study carried out by Robertson et al, findings from the 
complete cohort of 412 muscle-invasive bladder cancer cases 
revealed that mutations in the DNA repair genes ATM 
(n = 57; 14%) and ERCC2 (n = 40; 10%), and deletions in 
RAD51B (n = 10; 2%) were significant.55
It was found that all nonsilent somatic ERCC2 muta-
tions were missense, and many could be mapped within the 
conserved helicase domain. Dominant negative effects on 
ERCC2 function were observed.56 Thus, bladder cancer 
missense mutations in ERCC2 were associated with improved 
response to cisplatin-based chemotherapy. However, ERCC2 
mutations are distributed across the gene, and the functional 
impact of most individual ERCC2 mutations is unknown. 
Recently, Li et al reported developing a microscopy-based 
TABLE 2.3.  Currently Recommended Predictive Molecular Testing for Gastric, Esophageal, and Gastroesophageal Junction 
Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
HER2 Gene 
amplification
Workup any time (F)ISH Particularly if trastu-
zumab therapy is being 
considered
Lower level, wide 
acceptance
Gastric, esophageal, 
and gastroe-
sophageal junction 
cancers
PD-L1 (CD274) 
and HER2 
protein
Expression Workup any time 
for suspected or 
documented, inoper-
able, locally advanced, 
recurrent, or metastatic 
adenocarcinoma
IHC, FISH HER2-negative status 
corresponds with higher 
PD-L1 expression rates; 
together with MMR, 
HER2 is a potential 
biomarker for anti–PD-L1 
therapy
Lower level, wide 
acceptance
Gastric, esophageal, 
and gastroe-
sophageal junction 
cancers
Abbreviations: dMMR, deficient mismatch repair; (F)ISH, (fluorescence) in situ hybridization; IHC, immunohistochemistry; MMR, mismatch repair; PD-L1, 
programmed death-1 ligand.
aPatients who have gastric cancer with dMMR and HER2-negative status exhibited higher PD-L1 expression rates. These findings indicate that MMR and HER2 sta-
tus might be potential biomarkers for anti–PD-L1 therapy. Pembrolizumab treatment is approved for patients whose (gastric) tumors express PD-L142 (levels ≥1 
using the US Food and Drug Administration-approved IHC test).
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assay that measures the nucleotide excision repair function 
of clinically observed ERCC2 mutations. Most helicase 
domain mutations impaired the function. In addition, a 
preclinical ERCC2-deficient bladder cancer model showed 
that ERCC2 loss was sufficient to drive cisplatin sensitivity. 
Thus, ERCC2 was concluded to be a predictive biomarker in 
bladder cancer. Moreover, this study underscores the impor-
tance of combining genomic and functional approaches in a 
co-clinical trial to guide precision oncology for conventional 
chemotherapy agents. Current evidence presented here 
supports the idea that ERCC2 and ATM are potentially 
useful markers in muscle-invasive bladder cancer.55-57
Prostate cancers. It was recently reported that patients with 
metastatic castration-resistant prostate cancer (mCRPC) 
harboring germline mutations in BRCA1/BRCA2 and ATM 
have superior clinical outcomes after first-line treatment 
with abiraterone and enzalutamide (see Table 2.5).58 The 
authors suggested that this improved response is likely driven 
by mutations in BRCA1, BRCA2, and ATM. Because these 
conclusions were based on only 9 patients harboring BRCA/
ATM germline mutations and the study was not entirely 
prospective, these findings require prospective validation in 
larger patient cohorts. A separate, small, retrospective study 
found that all responders to poly(adenosine diphosphate 
[ADP]-ribose) polymerase (PARP) inhibitor therapy 
harbored BRCA2 mutations, whereas nonresponders did 
not.59 However, it was agreed that the functional relevance 
of mutations in DNA repair genes other than BRCA2 
should be considered before committing to PARP inhibitor 
therapy.
At the American Society of Clinical Oncology 2018 
meeting, De Bono et al60 reported preliminary findings from 
the KEYNOTE-199 phase 2 trial comparing  responses 
to the immune checkpoint inhibitor pembrolizumab 
in patients who had mCRPC with or without tumor 
 expression of PD-L1. Thus, pembrolizumab showed anti-
tumor activity and disease control with acceptable safety in 
 patients with docetaxel-refractory mCRPC, regardless of 
PD-L1 status. Of note, the response rate was numerically 
higher in patients with somatic BRCA1/BRCA2 or ATM 
mutations (12%), indicating that these could be predictive 
markers of response to checkpoint inhibitors. It can be seen 
from Table 2.561 that testing of BRCA1/BRCA2 is NCCN 
recommended. Testing of ATM is also suggested but not yet 
NCCN recommended.
Gynecologic cancers
Endometrial cancers. As noted above (see Microsatellite 
instability high tumors and DNA mismatch repair), the 
presence or absence of MSI should be determined through 
universal tumor molecular testing in every patient with 
uterine cancer (see Table 2.6).62 Approximately 2% to 5% 
of uterine cancers are because of Lynch syndrome, caused 
by germline mutations in MLH1, MSH2, MSH6, or PMS2. 
Abnormalities in MLH1 should prompt hypermethylation 
testing, as this can also cause tumors to be MSI-H in 
the absence of a germline mutation. The detection of a 
germline mutation affects subsequent screening for colon 
and ovarian cancer and prompts cascade testing to identify 
other affected family members. The presence of MSI-H 
because of either a germline mutation or hypermethylation 
provides an indication for pembrolizumab in the setting 
of recurrent uterine cancer, based on site-agnostic FDA 
approval granted in 2017.13 Women with POLE-aberrant 
endometrial cancers demonstrate a favorable prognosis and 
may require less aggressive therapy, although this remains 
theoretical at present. Identification of hotspot mutations 
in genes such as BRAF, KRAS, PIK3CA, and PTEN may 
correlate with biological behavior but are not yet targetable. 
TABLE 2.4. Currently Recommended Predictive Molecular Testing for Pancreatic Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
BRCA1 and 
BRCA2
Mutation 
(somatic and 
germline)
Initial workup if the 
patient has a 
strong family 
history on initial 
diagnosisa
NGS A known germline mutation 
could help guide therapy 
(eg, PARP and other DDR 
enzyme inhibitors). In 
October 2018, olaparib 
was approved for the 
treatment of patients with 
germline BRCA-mutated, 
metastatic pancreatic  
cancer that has not  
progressed after first-line,  
platinum-based 
chemotherapy
Nine percent of pancreatic 
cancers harbor a germline or 
somatic BRCA1 or BRCA2 
mutation, and this has an  
impact on response to 
therapy. BRCA testing in 
patients who are still  
responsive to cytotoxic 
therapy is becoming 
standard practice. The use of 
PARP inhibitors, specifically 
olaparib, in these patients is 
an option
Pancreatic 
adenocarcinoma
Abbreviations: DDR, DNA damage repair; NGS, next-generation sequencing; PARP, poly(adenosine diphosphate-ribose) polymerase.
aHaving at least one close relative with prostate cancer (possibility of germline mutations) and/or at least one close relative with breast, ovarian, or pancreatic 
cancer (possibility of a BRCA2 germline mutation) or with colorectal, endometrial, gastric, ovarian, pancreatic, small bowel, urothelial, kidney, or bile duct cancer 
(possibility of Lynch syndrome through germline mutations in MLH1, MSH2, MSH6, or PMS2) is a risk-factor.
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Phase 2 data demonstrate activity of mTOR inhibitors in 
endometrioid carcinoma of the uterus, but these trials were 
not assay-directed to determine whether molecular testing 
can select for potential activity.64
Ovarian cancers. The presence of pathogenic mutations 
in BRCA-related genes identify an important subset of high-
grade serous epithelial ovarian cancers that have a specific 
biology, natural history, and susceptibility to platinum 
and PARP inhibitors. The spectrum of mutations in this 
category includes those in BRCA1, BRCA2, RAD51C, 
RAD51D, BARD1, BRIP1, PALB2, MLH1, MSH2, MSH6, 
PMS2, and STK11 (see Table 2.7).65-67 Patients with these 
mutations have an improved prognosis with a higher 
likelihood of platinum sensitivity and long-term survival. 
Homologous recombination (HR)–deficient (HRD) 
tumors act similarly to tumors that have BRCA-related 
mutations and may serve as a surrogate for platinum 
sensitivity. Identification of these mutations directly affects 
therapy, as patients should be considered for treatment 
with PARP inhibitors immediately after upfront therapy 
with platinum and a taxane, based on the improved 
progression-free survival (PFS) observed in the SOLO-1 
trial (Olaparib Maintenance Monotherapy in Patients 
TABLE 2.5. Currently Recommended Predictive Molecular Testing for Prostate Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
BRCA1 and 
BRCA2
Mutation 
(somatic and 
germline)
Initial workup: If the 
patient has a strong 
family history on 
initial diagnosisa
NGS A known germline mutation could help 
guide therapy (eg, PARP and other DDR 
enzyme inhibitors)
Lower level; 
wide 
acceptance
Prostate cancers
If the patient has  
metastatic, 
castration-resistant 
disease
ATM Germline 
mutation
Initial workup show-
ing strong family 
history
If patient has meta-
static castration-
resistant disease
NGS NCCN guidelines recommend inquir-
ing about known BRCA1/BRCA2 
mutations in a patient’s family for 
prostate cancer early detection61 and 
Na et al63 proposed that, if a patient’s 
family member died of prostate 
cancer before age 75 y, a genetic 
test of BRCA1BRCA/2 and ATM is 
recommended
Lower levelb Prostate cancers
Known BRCA1/BRCA2 and ATM 
germline mutations could help guide 
therapy with PARP and other DNA  
damage–response enzyme inhibitors
Abbreviations: DDR, DNA damage repair; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; PARP, poly(adenosine diphos-
phate-ribose) polymerase.
aHaving at least one close relative with prostate cancer (possibility of germline mutations) and/or at least one close relative with breast, ovarian, or pancreatic 
cancer (possibility of a BRCA2 germline mutation) or with colorectal, endometrial, gastric, ovarian, pancreatic, small bowel, urothelial, kidney, or bile duct cancer 
(possibility of Lynch syndrome through germline mutations in MLH1, MSH2, MSH6, or PMS2) is a risk-factor.
bAlthough ATM testing is not yet recommended by the NCCN as a predictive measure, Na et al63 showed that germline BRCA2 and ATM mutations distinguish 
lethal from indolent prostate cancers and are associated with shorter survival times and earlier age at death. Antonarakis et al58 reported that patients with 
metastatic, castration-resistant prostate cancer harboring germline mutations in BRCA1/BRCA2 and ATM have superior clinical outcomes after first-line treat-
ment with abiraterone and enzalutamide.
TABLE 2.6. Currently Recommended Predictive Molecular Testing for Endometrial Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
ESR1 (ER) Expression In the stage III, IV,  
and recurrent 
disease settings
IHC ER positivity predicts 
response to endocrine 
therapy
Lower level, wide 
acceptance
Uterine neoplasms, 
endometrial carcinoma
PMS2 (Lynch 
syndrome, MMR 
gene)
Expression Upon diagnosis or 
upon recurrence if  
not previously 
tested
IHC Loss of PMS2 positivity 
indicates MMR, possible 
Lynch syndrome, and 
susceptibility to  
checkpoint inhibitors
Recommended by 
SGO Clinical 
Practice 
Statement
Uterine neoplasms, 
endometrial carcinoma
Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; MMR, mismatch repair; SGO, Society of Gynecologic Oncology.
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With BRCA Mutated Ovarian Cancer Following First 
Line Platinum Based Chemotherapy; Clini calTr ials.gov 
identifier NCT01844986).68 This international superiority 
trial showed a 70% reduction in risk of ovarian cancer 
progression in women with BRCA germline or somatic 
mutations who received maintenance olaparib after primary 
therapy with paclitaxel and carboplatin. Conversely, patients 
without BRCA-related mutations may be better served 
by antiangiogenic therapy with bevacizumab concurrent 
with upfront platinum and taxane therapy followed by 
maintenance bevacizumab therapy (Gynecologic Oncology 
Group study 0218 [GOG-7]).69,70
In the recurrent setting, PARP inhibitors (olaparib and 
rucaparib) as monotherapy were first approved for ovarian 
cancer patients with BRCA1/BRCA2 mutations or HRD. 
This indication has now been expanded to include olapa-
rib, rucaparib, and niraparib as switch maintenance ther-
apy for patients with platinum-sensitive ovarian cancer who 
have responded to platinum in the second-line or third-line 
setting.65-67,71
The identification of BRCA-related gene mutations is 
also necessary to perform cascade testing on family mem-
bers to identify affected family members who may be can-
didates for risk-reducing surgery and surveillance to prevent 
subsequent ovarian, tubal, peritoneal, and breast cancer.
Evaluation of PD-1 and PD-L1 status is useful in patients 
with ovarian cancer because pembrolizumab is approved 
for patients with MSI-H tumors based on a site-agnostic 
label. Single-agent activity for PD-1 inhibitors has been 
limited in patients with ovarian cancer, but checkpoint 
inhibitors are under study in the JAVELIN trials. The 
combination of PARP inhibitors with checkpoint inhib-
itors has been investigated, and initial response rates of 
25% to 30% have been noted. The larger ATHENA trial 
(A Study in Ovarian Cancer Patients Evaluating Rucaparib 
and Nivolumab as Maintenance Treatment Following 
Response to Front-Line Platinum-Based Chemotherapy; 
Clini calTr ials.gov identifier NCT03522246) of mainte-
nance rucaparib and nivolumab therapy is currently accru-
ing patients with ovarian cancer who have responded to 
front-line, platinum-based chemotherapy.
Although initial trial results using MEK inhibitors in 
the treatment of patients with low-grade serous carcino-
mas have been disappointing, multiple studies are ongoing 
investigating MEK inhibitor monotherapy and combi-
nation therapy. Other rare ovarian cancers have different 
molecular profiles, but targeted therapies remain largely 
unstudied.
Cervical cancers. The treatment of patients with recurrent 
cervical cancer has been problematic, and their prognosis 
is dismal. Bevacizumab was approved for recurrent disease 
in combination with platinums, taxanes, and topotecan; 
however, no molecular markers have yet been found that 
can predict patient treatment response. Pembrolizumab 
was FDA-approved in 2018 for patients with recurrent and 
metastatic cervical cancer who had disease progression on 
or after chemotherapy and whose tumors expressed PD-L1, 
based on a 14% objective response rate seen in KEYNOTE 
158 (Study of Pembrolizumab [MK-3475] in Participants 
With Advanced Solid Tumors; Clini calTr ials.gov 
identifier NCT02628067). Promising data also exist for 
single-agent nivolumab, which demonstrates a 26% response 
rate in the recurrent setting (Clini calTr ials.gov identifier 
NCT02488759). Trials evaluating combination therapy 
with nivolumab and ipilimumab are currently underway.
Breast cancers
The well-established biomarkers that drive treatment deci-
sions for patients with breast cancers are estrogen receptor 
(ER) expression, progesterone receptor (PR) expression, 
and human epidermal growth factor receptor-2 (HER2) 
overexpression or amplification in the tumor (see Table 2.8). 
Determination of ER, PR, and HER2 status is recom-
mended for all newly diagnosed invasive breast cancers and 
for any recurrences when feasible. These are routinely used 
to predict response to therapy and guide treatment planning 
for patients with breast cancer.
Some new markers that show promise for future use in 
breast cancer are the androgen receptor (AR), ESR1, and 
PD-L1. Overexpression of AR occurs in a subset of triple- 
negative breast cancers (TNBC).72 Clinical trials of AR-
targeted treatments have shown promising preliminary 
results in patients with metastatic, AR-positive TNBC.73 
Mutations in ESR1 occur in the ligand-binding domain of 
the ER and can lead to a ligand-independent, constitutively 
active form of the ER. This is a potential mechanism of resis-
tance to aromatase inhibitors. De novo ESR1 mutations have 
been most commonly detected during or after treatment with 
aromatase inhibitors for hormone receptor-positive breast 
cancer.74 The treatment implication is to consider using se-
lective ER downregulators that target ER directly in the set-
ting of an ESR1 mutation. The role of PD-L1 as a predictive 
biomarker for the treatment of patients with breast cancer 
using checkpoint inhibitors will be further delineated with 
several maturing trials evaluating immune checkpoint block-
ade in the treatment of breast cancer. In addition, multipa-
rameter genomic assays, such as Oncotype DX (Table 2.8), 
MammaPrint, and Prosigna (formerly called PAM 50), 
are being used routinely for decision making in early-stage 
breast cancer. MammaPrint and Prosigna are prognostic 
for recurrence of tumors that are lymph node negative, have 
1 to 3 positive lymph nodes, or are ER-positive but HER2-
negative. Additional multigene assays used for consider-
ation of adjuvant therapy in patients with breast cancer are 
EndoPredict and the Breast Cancer Index.
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Central nervous system cancers
Although broad panels are often appropriate and especially 
meaningful in the metastatic setting when conventional 
therapy has failed, more limited panels may be a considera-
tion (see Table 2.975,76). This can be exemplified by central 
nervous system tumors, in which genetic alterations are not 
just prognostic or predictive, but diagnostic. Before 2016, 
the World Health Organization (WHO) classification 
 relied strictly on histologic features to differentiate  tumors 
of astrocytic and oligodendroglial lineage.77 Although 
patients have significantly different treatment paradigms 
and survival depending on which of these tumor lineages 
they harbor,78 occasionally features from both lineages can 
be found within the same tumor, resulting in a diagnosis of 
a “hybrid” oligoastrocytoma. This is further compounded by 
high interobserver discordance; thus, some institutions di-
agnose this entity more frequently than others.79 By com-
bining both genotype and classical histologic findings, it is 
now possible to diagnose nearly all of these tumors to be 
compatible with either oligodendroglioma or astrocytoma. 
This has resulted in modifications to the WHO classification 
in 2016 to include both histologic phenotype and  molecular 
genotype with consideration of IDH mutation, 1p19q 
codeletion, ATRX loss, and TP53 mutation when diagnosing 
gliomas.75 Furthermore, epigenetic silencing of the promoter 
of the methyl-guanine methyl transferase gene MGMT  
by gene promoter methylation is frequently tested 
because it is highly prognostic and also predictive, cor-
relating with a response to or benefit of alkylating agent 
chemotherapy.76
It has been found that most glioblastomas have potential 
actionable genomic alterations.80,81 A recent NGS analy-
sis using a 315-gene panel found that, of 43 patients, 95% 
had at least 1 therapeutically actionable genomic alteration 
of a median of 4.5 genomic alterations per patient. The 
most common genomic alteration detected was in EGFR 
(40%). Genotype-directed treatments were prescribed 
in 13 patients, representing a 30% treatment decision 
 impact. Treatment with targeted agents—including ever-
olimus as a single agent and in combination with erlotinib, 
TABLE 2.8. Currently Recommended Predictive Molecular Testing for Breast Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
ER Expression Noninvasive,  
invasive, early 
stage, metastatic
IHC Predictor of response to  
endocrine therapy
High-level,  
wide acceptance
Noninvasive and invasive 
breast cancer, stage I-IV
PR Expression Invasive, early stage, 
metastatic
IHC Predictor of response to  
endocrine therapy
High-level,  
wide acceptance
Invasive breast cancer, 
stage I-IV
HER2 Gene 
amplification
Invasive, early stage, 
metastatic
ISH Predictor of response to  
HER2-targeted therapy such as 
trastuzumab, pertuzumab,  
lapatinib, or trastuzumab 
emtansine
High-level,  
wide acceptance
Invasive breast cancer, 
stage I-IV
HER2 (ERBB2) Protein 
expression
Invasive, early stage, 
metastatic
IHC Predictor of response to  
HER2-targeted therapy such as 
trastuzumab, pertuzumab,  
lapatinib, or trastuzumab 
emtansine
High-level,  
wide acceptance
Invasive breast cancer, 
stage I-IV
BRCA1 and 
BRCA2
Germline 
mutation
Metastatica NGS Predictor of response to PARP 
inhibitor
High-level,  
wide acceptance
Invasive breast cancer, 
stage IV
Oncotype Dx Gene 
expression
Hormone 
receptor-positive, 
HER2-negative
RT-PCR Prognostic for recurrence in lymph 
node–negative ER-positive/
HER2-negative; predictive of 
chemotherapy benefit in lymph 
node–negative ER-positive/
HER2-negative
High-level,  
wide acceptance
Stage I, II ER-positive/ 
PR-positive, 
HER2-negative
Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; NGS, next-generation sequencing; ISH, in situ hybridization; PARP, poly (ADP-ribose) poly-
merase; PR, progesterone receptor; RT-PCR, reverse transcription polymerase chain reaction.
aBRCA status can be assessed in early-stage disease (see National Comprehensive Cancer Network guidelines), but PARP inhibitors are not administered in 
this setting. For genetic/familial high-risk assessment (breast and ovarian), the following mutations are assessed in a gene panel (these markers are primarily 
 homologous repair deficiency-related):
BRCA1/2 TP53 ATM NBN RAD51C MLH1, MSH2, MSH6, PMS2, 
EPCAM deletion
MUC16 SKT11 BRIP1 NF1 RAD51D MLH1, MLH2, MSH6, PMS2
PTEN CDH1 CHEK2 PALB2 CDK4/6 EPCAM (TACSTD1) deletion
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afatinib, palbociclib, trametinib, and BGJ398—elicited no 
response.82
A fusion between Brevican (BCAN) and NTRK1 is a 
potent oncogenic driver of high-grade gliomas and confers 
sensitivity to entrectinib.83 A case report of a BCAN-NTRK1 
fusion in glioneuronal tumors highlights its clinical impor-
tance as a novel, targetable alteration,84 and an open-label, 
multicenter, global phase 2 basket study of entrectinib for 
the treatment of patients with locally advanced or meta-
static solid tumors that harbor NTRK1/NTRK2/NTRK3, 
ROS1, or ALK rearrangements (Clini calTr ials.gov identifier 
NCT02568267) is currently recruiting glioma patients.
For pediatric low-grade gliomas, BRAF V600E is a 
potentially highly targetable tumor mutation, which was 
detected in 17% of patients who exhibited poor outcome on 
receipt of chemotherapy treatment.85 In a recent evaluation 
of dabrafenib in a phase 1/2 trial that included 32 children 
with relapsed or refractory, low-grade gliomas, findings 
of an objective response rate of 38% and stable disease in 
another 44% of patients are extremely exciting. It is encour-
aging that these drugs could be effective agents that allow 
us to replace chemotherapy entirely for pediatric glioma.86
Other central nervous system types for which molecular 
profiling has a role include ependymoma (RELA fusion), 
diffuse midline cerebellar gliomas (histone 3 mutations), 
medulloblastoma (WNT vs SHH activated), and ependy-
moma (C19MC amplification). Although many of these 
tumors inevitably recur and a broader panel may be useful 
at some point in the course of the disease to define clinical 
trial options, obtaining a limited panel that contains the 
molecular alterations considered within the WHO criteria 
remains a reasonable option.
We certainly see the potential implication of molecular 
profiling for a routine part of therapeutic decision making 
beyond classification and prognostic prediction for patients 
with glioma. Of other mutations tested, the epidermal 
growth factor gene EGFR variant vIII encodes a promising 
molecular target. EGFR amplification could be useful in 
the treatment of glioblastomas. However, agents targeting 
EGFR signaling pathways have displayed limited or no 
therapeutic efficacy in glioblastoma clinical trials. ABT-
414 (an investigational, anti-EGFR monoclonal antibody 
drug conjugate) alone87 or in combination with temozolo-
mide showed a trend toward improved survival and was 
safely administered with radiation therapy.88,89
The BRAF V600E mutation, which is analyzed using 
NGS, is predictive and prognostic for low-grade pediatric 
glioma. This mutation is frequently found in gangliogliomas 
and in about two-thirds of grade II xanthroastrocytomas. It 
is assumed that this alteration constitutively activates the 
RAS/RAK/MEK/ERK kinase pathway. When BRAF 
kinase inhibitor treatment effects are validated within low-
grade glioma, the drug could transform the BRAF V600E TA
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mutation from a diagnostic marker to predictive marker of 
response to therapy.90
Sarcomas
Sarcomas are heterogeneous cancers comprising over 50 
diverse histological subtypes (see Table 2.10). As a group, 
they have a low occurrence incidence and are considered 
rare cancers. Although there is some crossover, pediatric 
and adult sarcomas have distinctly different histologies as 
well as different genetic drivers. The majority of genomic 
variations (translocations, CNVs, complex karyotypes, etc) 
provide important predictive diagnostic information rather 
than potential therapeutic targets. Thus, EWSR1-FLI1 (for 
Ewing sarcoma), PAX3/PAX7-FOX01 (alveolar rhabdo-
myosarcoma), SYT-SSX2 (monophasic synovial sarcoma), 
SYT-SSX1/SSX2 (biphasic synovial sarcoma), and TLS-
FUS/CHOP (myxoid liposarcoma) fusions are diagnostic 
markers that should be tested at initial workup using RNA 
sequencing techniques, particularly FISH. There are sev-
eral prominent exceptions to this diagnosis-only rule in 
gastrointestinal (GI) stromal tumors, in which mutations 
in KIT (particularly exon 11) and PDGFRA are notable 
biomarkers for therapeutic intervention with the tyrosine 
kinase inhibitors imatinib and sunitinib.
Head and neck cancers
PD-1 is highly expressed in head and neck squamous cell 
carcinomas (HNSCCs) and, in 2016, the PD-1 inhibitors 
nivolumab91 and pembrolizumab92 were both approved for 
the treatment of HNSCC that has metastasized or  recurred 
on or after treatment with platinum chemotherapy (see 
Table 2.11). PD-L1 testing is now recommended in  patients 
undergoing workup for metastatic HNSCC, with the 
 intention of offering pembrolizumab as a treatment  option 
to those with PD-L1–positive tumors.
EGFR is reportedly overexpressed in between 90% 
and 100% of HNSCCs.93 Accordingly, cetuximab is an 
approved targeted therapy for this disease and is usually 
administered regardless of EGFR mutation testing. 
HNSCCs can develop resistance to cetuximab. Activation 
of other EGFR family members (HER2, HER3) can play 
a role in this resistance, as can c-MET, insulin growth fac-
tor receptor (IGFR), and PI3K.94 PIK3CA is frequently 
mutated in HNSCC and plays a key role in the progression 
of HNSCC.95,96 Targeted agents against all these markers 
have been developed and have undergone or are undergo-
ing various phases of clinical testing. Human papillomavirus 
(HPV)-related HNSCCs are increasing in incidence and 
have different oncogenic processes compared with HPV-
unrelated HNSCCs. Patients with HPV-positive HNSCCs 
respond better to treatment and have a better prognosis 
than their HPV-negative counterparts. Therefore, for the 
sake of disease diagnosis, treatment, and management, it is 
useful to accurately discriminate between the HPV-positive 
and HPV-negative HNSCCs, which can be done through 
tumor P16 testing by IHC; thus, P16 positivity corresponds 
to HPV positivity.97
Melanomas
To date, the only FDA-approved predictive biomarker in 
patients with advanced melanoma is BRAF genotyping 
(see Table 2.12). Approximately one-half of melanomas 
that originate from cutaneous primary sites will harbor a 
BRAF V600 mutation.98 This leads to constitutive activa-
tion of the MAPK pathway and increased cell prolifera-
tion, metastasis, and survival mechanisms. Vemurafenib, 
dabrafenib, and encorafenib are BRAF-targeted thera-
pies that preferentially inhibit cells harboring the BRAF 
V600 mutation. It is important to be aware that selective 
TABLE 2.10. Currently Recommended Predictive Molecular Testing for Sarcomas
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
MDM2, 
CDK4a
Amplification At diagnosis NGS Possible clinical trial with 
CDK4/CDK6 inhibitor
Wide acceptancea Well-differentiated liposarcoma, 
dedifferentiated liposarcoma
IDH1/IDH2a Mutation At diagnosis NGS Possible trial with IDH1 
inhibitor
Wide acceptancea Chondrosarcoma
Abbreviation: NGS, next-generation sequencing.
aThese tests are not strictly specified in the National Comprehensive Cancer Network guidelines but are widely accepted among the sarcoma community.
TABLE 2.11. Currently Recommended Predictive Molecular Testing for Head and Neck Cancers
BIOMARKER TEST DETECTS WHEN TECHNOLOGY RECOMMENDATIONS EVIDENCE CANCER TYPE
PD-L1 Protein 
expression
Metastatic 
workup
IHC Recurrent, unresectable, or metastatic (with no 
surgery or radiation therapy option); second-line or  
subsequent therapy options: pembrolizumab for 
PD-L1–positive disease
Lower level, wide 
acceptance
Cancer of the 
nasopharynx
Abbreviation: IHC, immunohistochemistry; PD-L1, programmed death 1 ligand.
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inhibitors of BRAF encoded by mutant BRAF V600 can 
cause paradoxical activation of the MAPK pathway in cells 
that are BRAF V600 wild-type (particularly if they harbor 
a RAS mutation). This effect occurs through RAF dimeri-
zation, leading to increased cell proliferation rather than 
inhibition.99 The combination of selective BRAF inhibi-
tors with MEK1/MEK2 inhibitors is now FDA approved 
only for patients with BRAF V600-mutant melanoma. In 
patients with resected, stage III, BRAF V600E/V600K–
mutant melanoma, dabrafenib plus trametinib improves 
relapse-free survival by 53%.100 Similarly, dabrafenib plus 
trametinib and other BRAF/MEK inhibitor combinations 
have demonstrated objective response rates of up to 68% 
in patients with unresectable advanced BRAF V600E/K 
mutant melanoma.101
Other oncogenic driver mutations have been identified in 
melanomas for which targeted therapies have demonstrated 
clinical activity. KIT mutations (and amplifications) have 
been identified in up to 20% of patients with advanced mel-
anoma, particular those with chronic sun-damaged, acral, or 
mucosal melanoma subtypes.102,103 Of note, KIT mutations 
are often seen across multiple exons, and hotspot mutations 
are not typically observed. This patient population has a 
reported response rate to imatinib of 21% to 29%.104-106 
Higher response rates were seen in individuals whose mel-
anoma harbored KIT exon 11 and 13 mutations. Another 
important oncogene, NRAS, is mutated in approximately 
20% of melanomas—most commonly at the Q61 position.107 
Direct targeting of NRAS has proven difficult, but clinical 
activity has been demonstrated by targeting the downstream 
MAPK pathway with MEK1/MEK2 inhibitors. The MEK 
inhibitor binimetinib showed superior clinical outcomes 
compared with dacarbazine.108 However, the objective 
response rate of binimetinib was only 15%, and this agent 
has not yet been approved by the FDA for this indication.
With regard to predictive biomarkers for immune 
checkpoint therapies in melanoma, several have shown 
enrichment for greater clinical activity, mostly in post hoc 
or retrospective analyses, but have not been approved by 
the FDA for routine clinical use.109 These include positive 
PD-L1 IHC, immune gene expression profiles, and high 
tumor mutational burden (TMB) (see The role of TMB—
an emerging biomarker, below) by targeted exome sequenc-
ing. For example, response rates to anti-PD-1/PD-L1 
therapy were 81%, 36%, and 10% for patients whose tumors 
had >23.1 mutations per megabase (MB), 3.3 to 23.1 muta-
tions per MB, and <3.3 mutations per MB, respectively.110 
However, patients with low or negative biomarkers can 
still benefit from immune checkpoint therapies, and some 
studies have shown marginal differences between groups. 
The PD-L1 IHC analyses from the Checkmate 067 study 
demonstrate this concept well: response rates were 43% 
and 58% with nivolumab monotherapy in patients whose TA
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tumors had <5% PD-L1 staining versus >5% PD-L1 
staining, respectively.111 Biomarkers may be useful in the 
application of nivolumab/ipilimumab combination therapy 
over nivolumab monotherapy for patients with melanoma 
based on Checkmate 067 study data. Improvement in PFS 
with the combination approach was best seen in patients 
whose tumors harbored a BRAF V600 mutation or had 
<1% PD-L1 staining (hazard ratios, 0.62 and 0.68, 
respectively).
The Gray Area Between Research and Clinical 
Practice
Core clinical markers in current use by expert molecu-
lar profiling laboratories, the frequencies of these mark-
ers in a range of tumor lineages, and assay types used for 
their assessment can be found in Table 6 (Caris Molecular 
Intelligence). Many of the markers and their assays in 
Table 6 are essentially still classified as belonging in a 
“research” category, and the NCCN has not yet recommended 
universal testing for these genes. Nevertheless, they have 
been reported as actionable and useful by a general con-
sensus of experts in the research community. Because the 
use of broader gene panels and full-scale NGS is still in the 
gray area between research and clinical practice, it comes 
burdened with benefit-to-cost ratio controversies. The field 
is also evolving rapidly, with f luidity existing in the classifi-
cation of genes as clearly, possibly, or unlikely to be relevant 
to treatment considerations.
Until recently, approved genetic testing involved a small 
group of genetic tests carried out in patients with specific 
cancers for a specific therapeutic purpose. Firmly estab-
lished examples of mutational status being key to treat-
ment recommendations include pan-RAS testing (KRAS, 
NRAS, and HRAS) in patients with CRC to direct the use 
of anti-EGFR therapies cetuximab and panitumumab45 and 
HER2 testing in patients with breast cancer to direct the use 
of anti–HER2-targeted therapies, such as trastuzumab,112 
and tyrosine kinase inhibitor therapies, such as lapatinib.113 
TABLE 3. Frequency of MSI-H Status Across Cancer Typesa
% MSI-H (NO./TOTAL NO.)
CANCER TYPE VANDERWALDE 201810 BONNEVILLE 201711
All cancer types 3.0 (342/11,348) 3.8 (425/11,139)
NSCLC (adenocarcinoma/squamous cell carcinomab) 0.6 (12/1868) 0.5-0.6 (6/1065b)
Colorectal adenocarcinoma 5.7 (80/1395) –
Colon adenocarcinoma – 19.7 (85/431)
Rectal adenocarcinoma – 5.73 (9/157)
Pancreatic adenocarcinoma 1.2 (6/518) 0.0 (0/183)
Esophageal and esophagogastric junction carcinoma 0.0 (0/189) 1.6 (3/184)
Gastric adenocarcinoma 8.7 (16/184) 19.1 (84/440)
Liver hepatocellular carcinoma 2.7 (2/73) 0.8 (3/375)
Gastrointestinal stromal tumors (GIST) 0.0 (0/52) –
Ovarian surface epithelial carcinoma (serous cystadenocarcinomac) 1.1 (17/1517) 1.37 (6/437c)
Nonepithelial ovarian cancer 1.8 (1/56) –
Endometrial carcinoma 17.6 (155/879) 31.4 (170/542)
Cervical cancer (squamous cell carcinoma/endocervical adenocarcinomad) 3.6 (6/168) 2.6 (8/305d)
Breast carcinoma 0.6 (6/1024) 1.5 (16/1044)
Prostatic adenocarcinoma 2.1 (4/191) 0.6 (3/498)
Bladder cancer 0.0 (0/143) 0.5 (2/412)
Glioblastoma (multiforme) 0.7 (3/427) 0.3 (1/396)
(Skin cutaneous) melanoma 0.0 (0/345) 0.6 (3/470)
Head and neck squamous carcinoma 0.0 (0/111) 0.8 (4/510)
Sarcoma – 0.78 (2/255)
Abbreviations: MSI-H, microsatellite instability-high; NO./TOTAL NO., number of MSI-H tumors/total number of tumor samples tested; NSCLC, non–small cell 
lung cancer.
aData from: Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared 
with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7:746-75610; and Bonneville R, Krook MA, Kautto EA, et al. Landscape of micro-
satellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1-15. doi:10.1200/PO.17.00073 .11
bBonneville 2017 quoted testing lung adenocarcinoma and squamous cell carcinoma, which are subtypes of NSCLC. Vanderwalde 2018 quoted general NSCLC.
cBonneville 2017 quoted testing serous cystadenocarcinoma, which is a subtype of ovarian surface epithelial carcinoma. Vanderwalde 2018 quoted general 
ovarian surface epithelial carcinoma.
dBonneville 2017 quoted testing squamous cell carcinoma and endocervical adenocarcinoma, which are subtypes of cervical cancer. Vanderwalde 2018 quoted 
general cervical cancer.
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It took many years and a large number of trials involving 
many patients before pan-RAS and HER2 testing became 
a standard treatment-predictive approach. Other examples 
of molecular testing used in standard clinical practice are 
detailed above (see Disease-Specific Biomarkers). However, 
as genetic testing evolved into whole genome sequencing, 
advances in computer technology allowed small-capacity 
assays to evolve into automated, high-throughput assays with 
large-scale data collection, classification, storage, and analy-
sis. Thus, real-time, broad gene panel testing combined with 
relevant patient clinical data are now providing an unprec-
edented wealth of information. However, the interpretation 
of the meaning of results is limited by the finding that rela-
tively small pools of evidence are available to validate most 
markers and their paired targeted therapies. Larger studies 
and collaborative efforts are certainly needed to further and 
more widely validate these broader panel markers and gene 
expression profiles and to integrate them and their targeted 
therapies into clinical practice (see Absence of Randomized, 
Controlled Clinical Trials, below). The immediate goal 
of testing is to translate genetic findings into potentially 
effective therapy decisions for today’s patients. Meanwhile, 
numerous proof-of-principle trials currently are in progress 
or in development. One key to accelerating the application 
of this knowledge is real-time national and international 
partnerships between cancer researchers and pharma-
ceutical companies to perform broad-panel profiling and 
elucidate targeted patient therapies. Concurrently, data pool-
ing is mandatory using universal data-sharing capabilities to 
maximize the utility of these findings and generate large 
pools of evidence (see Data Sharing, below). Successes and 
failures alike will provide a more complete picture, and the 
result will take us steps closer to effective cancer treatment—
and cures. This model is already in practice in the form of 
basket trials.
Oncology Basket Trials and Precision Medicine
Current oncology basket trials test therapies across a range 
of populations using biomarker-driven designs. Such tri-
als choose biomarkers, which must have a clinically feasible 
assay, to attempt to enrich responses to a particular targeted 
therapy. The gathering of efficacy data across a range of 
populations translates to only one primary outcome end-
point, which simplifies the situation while increasing deduc-
tive power. These large-scale and small-scale, broad-panel 
molecular profiling trials include the National Cancer 
Institute’s Molecular Analysis for Therapy Choice (NCI-
MATCH) trial, the American Society of Clinical Oncology 
(ASCO) Targeted Agent and Profiling Utilization Registry 
(TAPUR) study, and the European Organization for 
Research and Treatment of Cancer–Screening Patients for 
Efficient Clinical Trial Access (EORTC-SPECTA) pro-
gram. These studies attempt to expand the boundaries of 
precision medicine and build evidence supporting the use of 
molecularly tailored therapy.
National Cancer Institute’s Molecular Analysis for 
Therapy Choice Trial
The novel, phase 2 NCI-MATCH (Molecular Analysis for 
Therapy Choice114) trial was initiated in August 2015 and is 
bringing public and private sectors together to enable access 
of physician researchers to investigational agents (in addition 
to approved agents) in an attempt to build the much sought-
after evidence supporting the effectiveness of matching 
TABLE 4. NTRK Frequencies in Selected Cancersa
NTRK GENE TUMOR TYPE FUSION PARTNERSa FREQUENCY (NO./TOTAL NO.)b
NTRK1, n = 7 Gliomas TPM3, BCAN, MEF2D 0.3% (3/982)
Colorectal carcinoma TPM3 0.2% (2/1272)
Cervical carcinoma TPM3 1.5% (1/68)
Lung adenocarcinoma TPM3 0.0% (1/4073)
NTRK2, n = 10 Gliomas VCAN, GKAP1, KCTD8, NOS1AP, TBC1D2, SQSTM1 (n = 2),  
BCR (n = 2), PRKAR2A
0.9% (9/982)
Lung adenocarcinoma SQSTM1 0.0% (1/4073)
NTRK3, n = 8 Gliomas EML4, ETV6 0.2% (2/982)
Lung adenocarcinoma ETV6 0.0% (2/4073)
Secretory carcinoma (breast) ETV6 0.1% (1/769)
Uterine sarcoma SPECC1L 0.2% (1/478)
Cancer of unknown primary ETV6 0.4% (2/227)
Abbreviations: NO./TOTAL NO., number of tumors with fusion/total number of tumor samples tested.
aThese were fusion partners identified by Gatalica et al,18 and this is not a comprehensive list of all currently known NTRK fusion partners.
bThe frequency data presented here are in general consensus with previous studies, although they represent a much broader overview of frequency and types 
of NTRK fusions than these other studies due to the large volume of tumors studied (more than 11,000 patients were screened). Data from: Gatalica Z, Xiu J, 
Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32:147-153.2018.18
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targeted therapy to patient molecular profiles. The primary 
aim of the NCI-MATCH study is to evaluate the propor-
tion of patients with objective responses (ORs) to targeted 
therapies predicted to be mechanistically effective based on 
individual tumor genomic profiling. If the response rate to 
any mutation-matched therapy is at least 25%, this match 
will be tested in larger phase 2 trials. There are well over a 
thousand study locations across the United States, and phar-
maceutical and biotechnology companies are providing tar-
geted agents to enrolled patients across these sites. Patients 
are treated according to their profile (Table 7) and regard-
less of tissue origin or cancer type. New drugs of interest 
can be added to the “master” trial at any time. The trial is 
running under Clini calTr ials.gov identifier NCT02465060, 
where up-to-date information can be obtained.
Targeted Agent and Profiling Utilization Registry
The TAPUR study is an ongoing, nonrandomized, mul-
ticenter clinical trial that opened in 2016.115 This trial 
is testing the use of drugs already approved by the FDA 
that target a specific tumor mutation in individuals with 
 advanced cancer outside of the drug’s approved indica-
tion. Patients with a range of solid tumors as well as 
lymphomas and multiple myelomas are eligible for enroll-
ment. As with NCI-MATCH, treatment assignment in 
this study is based on an existing tumor mutation and not 
the organ from which the cancer originated. The study 
aim is to observe the real-world use of targeted therapies 
in any patient whose tumor tests positive for a selected 
genomic alteration that is known to be a drug target or 
has been shown to predict sensitivity to a drug available in 
this study. The primary outcome measure is the objective 
 response rate (defined as the percentage of participants in 
a cohort with a complete or partial response at 8 weeks 
postbaseline or with stable disease at 16  weeks or later 
postbaseline according to RECIST (Response Evaluation 
Criteria in Solid Tumors) (for solid tumors), international 
uniform response criteria (for multiple myeloma),116 and 
TABLE 5. Best Known Somatic Mutations That Could Also Be Germline Mutationsa
GERMLINE OR SOMATIC MUTATION RARE GERMLINE-ASSOCIATED SYNDROME MAIN CANCER APPLICABILITY
TP53 Li-Fraumeni Sarcomas, and cancers of the breast and brain
MSH2, MLH1, MSH6, PMS2, EPCAM Lynch Cancers of the GI tract (particularly colorectal),  
endometrium, ovary, brain, breast, and renal pelvis
BRCA1, BRCA2 Hereditary breast, ovarian, prostate, and  
pancreatic cancers
Cancers of the breast, ovary, prostate, and pancreas
PTEN Cowden Cancers of the breast, endometrium, and thyroid gland
APC, MUTYH Familial adenomatous polyposis Cancers of the colon and rectum, small intestine,  
stomach, brain, bone, and skin
CDH1 Hereditary diffuse gastric cancer Cancers of the stomach and breast
CDK4, CDKN2A Familial atypical multiple mole melanoma Melanoma, pancreatic adenocarcinoma, and cerebral 
astrocytoma
MEN1 Werner Pancreatic endocrine cancer and pituitary gland tumors
RB1 Retinoblastoma Eye cancer, pinealoma, osteosarcoma, melanomas,  
and soft-tissue sarcomas
RET Multiple endocrine neoplasia type 2 Medullary thyroid cancer, and pheochromocytoma
VHL Von Hippel-Lindau Kidney cancers and multiple noncancerous tumors
STK11 Peutz-Jeghers Cancers of the breast, colon and rectum, pancreas,  
and stomach and hamartomas
SDHD, SDHB, SDHC Familial paraganglioma Paragangliomas and pheochromocytomas
FLCN Birt-Hoge-Dube Chromophobe renal cell cancers
TSC1, TSC2 Tuberous sclerosis Angiofibromas, angiomyolipomas, giant cell astrocytomas
NF1 Neurofibromatosis type 1 Optic gliomas and neurofibromas
NF2 Neurofibromatosis type 2 Schwannomas, meningiomas, gliomas, neurofibromas
PTCH1 Gorlin Childhood primitive neuroectodermal tumors, skin basal 
cell carcinomas
BMPR1A, SMAD4 Juvenile polyposis Multiple noncancerous growths in the colon
Abbreviation: GI, gastrointestinal.
aTable adapted from: Lartigue J. Blurring the lines between germline and somatic mutations in cancer. Oncol Live. 2017;18. onclive.com/publications/oncology-live/ 
2017/vol-18-no-13/blurring-the-lines-between-germline-and-somatic-mutations-in-cancer. Accessed February 6, 2019.32
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TABLE 7. Broadening Molecular Profiling Boundaries—Biomarker-Targeted Therapy Matches
TARGETED MUTATION DRUG
NCI-MATCH trial: NCT02465060a 
 EGFR activating mutation Afatinib
 HER2 activating mutation Afatinib
 BRCA1 or BRCA2 mutations Adavosertib (AZD1775)
 FGFR pathway aberrations AZD4547
 NRAS12, NRAS13, NRAS61 mutation Binimetinib
 AKT mutation Capivasertib (AZD 5363)
 PIK3CA mutation Copanlisib
 PTEN mutation Copanlisib
 PTEN loss Copanlisib
 MET amplification Crizotinib
 MET exon 14 deletion Crizotinib
 ALK translocation Crizotinib
 ROS1 translocation or inversion Crizotinib
 BRAF V600E/V600R/V600K/V600D mutation Dabrafenib + trametinib
 DDR2 S768R, I638F, or L239R mutation Dasatinib
 NF2 inactivating mutation Defactinib
 PTEN mutation or deletion and PTEN expression GSK2636771 (PI3Kβ inhibitor)
 PTEN loss GSK2636771 (PI3Kβ inhibitor)
 FGFR mutation or fusion Erdafitinib
 FGFR amplification Erdafitinib
 NTRK1, NTRK2, NRTK3 gene fusions Larotrectinib (LOXO-101)
 Loss of MLH1 or MSH2 (by IHC) Nivolumab
 EGFR T790M or rare activating mutation Osimertinib
 CCND1, CCND2, CCND3 amplification & Rb expression Palbociclib
 CDK4 or CDK6 amplification and Rb protein Palbociclib
 HER2 amplification ≥7 copy numbers Pertuzumab + trastuzumab
 TSC1 or TSC2 mutation Sapanisertib
 mTOR mutation Sapanisertib
 cKIT exon 9, 11, 13, or 14 mutation Sunitinib
 PIK3CA mutation Taselisib
 GNAQ/GNA11 mutation Trametinib
 BRAF fusion or BRAF non-V600 mutation Trametinib
 NF1 mutation Trametinib
 HER2 amplification Trastuzumab emtansine
 SMO/PTCH1 mutation Vismodegib
TAPUR trial: NCT02693535b
 VEGFR mutation, amplification or overexpression Axitinib
 Bcr-abl, SRC, LYN, LCK mutations Bosutinib
 ALK, ROS1, MET mutations Crizotinib
 KRAS, NRAS, and BRAF (all wild type) Cetuximab
 Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations Dasatinib
 BRCA1/BRCA2 inactivating mutations; ATM mutations/deletions Olaparib
 MSI-high, high TML, and others Nivolumab and ipilimumab
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Lugano criteria (for non–Hodgkin lymphoma).117,118 
Table 7 details the genomic alterations (biomarkers) and 
targeted therapies of interest at the time of submission of 
this article for publication, although markers and thera-
pies are continually being refined as the study progresses. 
It is currently anticipated that TAPUR will  enroll 
over 2500 patients in total. The trial is running under 
Clini calTr ials.gov identifier NCT02693535, where up-to- 
date information can be obtained.
European Organization for Research and Treatment 
of Cancer–Screening Patients for Efficient Clinical 
Trial Access
EORTC-SPECTA is a collaborative European molecu-
lar screening program that coordinates several disease-
specific platforms with the aim of identifying actionable 
mutations and offering specific targeted therapy to  patients 
(Clini calTr ials.gov identifier NCT02834884).119,120 This is 
a large-scale basket trial that operates through one entry 
point that provides access to multiple studies and to high-
quality, annotated material for research purposes and 
provides longitudinal follow-up of patients to understand 
progression patterns.121
Targets of Special Interest: Emerging and in 
Current Practice
There are several novel biomarkers of great interest, many 
of which have found a niche in common practice but are 
continuing to reveal exciting connections and uses. We 
 expand on several these markers below.
Immune Markers and Immunotherapy
Programmed death–ligand 1 expression
The immune checkpoint PD-1/PD-L1 axis is a well- 
described inhibitory pathway that leads to T-cell exhaus-
tion in the tumor microenvironment.122 Typically, PD-1 on 
tumor-infiltrating cytotoxic T cells interacts with PD-L1 
on tumor cells, causing dampening of antitumor immunity 
(an adaptive immune response).123 Tumor types known to be 
immunogenic typically have relatively high rates of PD-L1 
positivity.124 However, although greater clinical activity 
of anti–PD-1 agents (nivolumab and pembrolizumab) and 
PD-L1 agents (avelumab, atezolizumab, and durvalumab) has 
been consistently observed in patients with PD-L1–positive 
disease,125,126 some clinical trials have found that patients 
with low PD-L1–expressing tumors can derive significant 
benefit from anti–PD-1/PD-L1 agents. Therefore, PD-L1 
IHC score alone is insufficient for patient selection in many 
tumor types. Assays have been developed to test for PD-L1 
expression, including the PD-L1 IHC assay with 28-8 
Dako (developed for nivolumab), 22C3 Dako (developed 
for pembrolizumab), SP142 Ventana (atezolizumab), SP263 
Ventana (durvalumab), and 73-10 Dako (avelumab). These 
assays can be used as a tool for physicians to assess which 
patients might have the largest chance of benefitting from 
anti–PD-1/PD-L1 agents. However, because each inhibitor 
requires its own individual PD-L1 IHC assay, it is useful to 
have an upfront working knowledge of which targeted ther-
apy is going to be used; otherwise the laboratory is required 
to run 5 different IHC tests, which raises costs and inef-
ficiencies. There are several scenarios in which the FDA 
has mandated that PD-L1 positivity is required before anti–
PD-1 agents are usable within approved indications. For 
example, patients with advanced, metastatic NSCLC can 
be treated in the front line with pembrolizumab monother-
apy only if their PD-L1 tumor proportion score (TPS) is 
>50% (Table 2.1).127 In the second-line setting, pembroli-
zumab is FDA approved for adult patients with tumors 
(eg, gastric tumors) (Table 2.342) that have a lower posi-
tive TPS score (>1%).128 Interestingly, nivolumab has been 
 approved as second-line therapy for select cancers regardless 
of their PD-L1 status.129,130 There is controversy over the 
TARGETED MUTATION DRUG
 CDKN2A, CDK4, CDK6 amplifications Palbociclib
 POLE/POLD1 mutations; high TML Pembrolizumab
 VEGFR1, VEGFR2, VEGFR3, PDGFRB, RET, KIT, RAF-1, BRAF mutations/amplifications Regorafenib
 PDGFR, VEGFR, CSF1R Sunitinib
 mTOR, TSC mutations Temsirolimus
 ERBB2 amplifications Trastuzumab and pertuzumab
 BRAF V600E mutations Vemurafenib and cobimetinib
Abbreviations: IHC, immunohistochemistry; MSI, microsatellite instability; NCI, National Cancer Institute; TML, tumor mutation load.
aNCI-MATCH trial: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma. 
Matches are as listed on clinicaltrials.gov/ct2/show/NCT02465060. Accessed February 6, 2019. After patient tumor molecular testing on a main screening 
protocol, those with actionable mutations are assigned to 1 of 35 treatment subprotocols.
bThe American Society of Clinical Oncology’s TAPUR trial: Testing the Use of US Food and Drug Administration-Approved Drugs That Target a Specific Abnormality 
in a Tumor Gene in People With Advanced Stage Cancer. Matches are as listed on clinicaltrials.gov/ct2/show/NCT02693535. Accessed February 6, 2019.
TABLE 7. Continued
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use and reliability of PD-L1 IHC as a predictive biomarker. 
This is because of multiple factors:
• First, performing a PD-L1 IHC assay on a single tumor 
site at one time point does not take into account the intra-
patient tumor heterogeneity that can exist and the vari-
ability in PD-L1 expression that can occur over time.131 
PD-L1 expression can be regulated by IFN-γ signaling 
from T-cell interactions and by several tumor-intrinsic 
pathways such as MAPK and PI3K/Akt signaling, as 
well as epigenetic factors.132
• A second issue is the range of antibody assays that have 
been developed124 and the need for standardization. 
There have been cross assay comparisons, particularly 
in NSCLC, for which the staining patterns were simi-
lar among the 28-8, 22C3, and SP142 antibodies.133,134 
However, SP142 staining of tumor cell membranes was 
shown to be weaker, resulting in fewer positive tumor 
cells than some other assays. The 73-10 antibody was not 
included in these analyses.
• A final issue is related to PD-L1 IHC scoring: how does 
one define a PD-L1–positive from a PD-L1–negative 
tumor? PD-L1 staining of immune cells in the tumor 
microenvironment, such as macrophages, gives a signal 
that is erroneously included in tumor PD-L1 assessment. 
This is the case for 22C3 and SP142 assays. To date, 
no approaches or thresholds reach sufficient sensitiv-
ity or specificity to be predictive of a high likelihood of 
response to a given drug. Providers need to be familiar 
with the individual PD-L1 assays and scoring used for 
each agent and tumor type when making patient deci-
sions based on PD-L1 results.
Microsatellite instability and deficient MMR
Microsatellites are lengths of DNA sequence that contain 
single nucleotide (mononucleotide) or sections of 2 or more 
nucleotide (dinucleotide, trinucleotide, tetranucleotide, or 
pentanucleotide) repeats (see Microsatellite instability-high 
tumors and DNA mismatch repair). When microsatellites 
contain a clonal change in several repeated DNA nucleo-
tide units, this results in MSI (tumors with such MSI are 
characterized as MSI-H, and this occurs when at least one 
of the MMR genes—MSH2, MLH1, MSH6, and PMS2—
are inactivated, causing dMMR).10 Since MSI-H was 
established as a possible biomarker, the MSI status of a 
tumor has always required microdissection and PCR-based 
detection strategies. For practical purposes, MSI is equiva-
lent to the loss of staining by IHC of at least one of the 
MMR genes because any lack of normal MMR protein 
expression signifies an abnormality in MMR and thus 
MSI. A sensitive and specific MSI assay by NGS has 
recently been developed that is comparable to the existing 
gold standard of PCR-based methods without requiring 
matched samples from tumor and normal tissues.10 MSI 
appears to be a generalized cancer phenotype in about 4% 
of all adult cancers in total. MSI-H tumors are associ-
ated with an improved prognosis in early-stage cancers. In 
Table 3,10,11 MSI-H frequency data for several different can-
cer types are compared between 2 studies. In both studies, 
patient DNA was originally sequenced by NGS; however, 
the study by Bonneville et al11 obtained and retrospec-
tively assessed sequencing data from The Cancer Genome 
Atlas (TCGA), the Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET) database, and 
444 other studies, whereas the study by Vanderwalde et al10 
retrospectively assessed data from commercial compre-
hensive sequencing profiles performed on patient tumors 
by Caris Life Sciences. It can be readily observed from 
Table 310,11 that the rate of MSI-H in tumors from differ-
ent tissue types is not always consistent between studies. In 
particular, this can be observed for gastric cancers, endo-
metrial cancers, breast cancers, and CRCs versus colon and 
rectal cancers. These study differences could be explained 
for the most part by sampling bias, the use of different data 
analysis techniques, or statistical variance. Vanderwalde 
et al10 certainly assessed a very sick patient population that 
was undergoing tumor profiling because of a bad progno-
sis and lack of obvious therapeutic options, whereas the 
patient population examined by Bonneville et al11 was not 
described as such and possibly consisted of patients with 
variable disease stages and prognoses; MSI-H patients tend 
to have a better prognosis than their microsatellite stable 
counterparts do, which would explain the lower percentage 
of MSI-H patients in the Caris data set compared with the 
TCGA data set. In addition, Vanderwalde et al10 combined 
colon and rectal cases in one analysis, possibly yielding a 
lower percentage of MSI-H than that seen by Bonneville 
et al11 for colon cancer alone. This highlights the potential 
for variability in biomarker assessment because of differ-
ent assay types and technologies, not just for MSI but also 
across the biomarker board.
The role of TMB—an emerging biomarker
TMB is certainly an interesting marker, and evidence 
of its importance is growing. However, methodologies 
assessing TMB are not widely available at present, and 
most clinical laboratories do not yet offer this assessment 
in their assay repertoire. Immunogenicity is certainly 
associated with mutation load, suggesting that an increase 
in the number of somatic mutations present in tumor cells 
increases potential recognition by the immune system.135 
Indeed, the presence of mutations in the tumor generates 
neoantigens (not expressed by normal cells), and the more 
mutations there are, the more the tumor is likely to be 
immunogenic. Furthermore, emerging evidence suggests 
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that a high TMB is associated with increased clinical 
activity of immune checkpoint inhibitors.136-140 TMB 
was shown to predict immune therapy efficacy in patients 
with melanoma,138 NSCLC,140 and GI cancers.141 There 
is ongoing discussion regarding the definition of “high” 
TMB for predictive purposes. Most studies report ≥17 
mutations per MB as high TMB, which is based on com-
paring TMB with MSI in patients with CRC. This, of 
course, also shows that high TMB is in strong concord-
ance with MSI-high in CRC. However, although TMB is 
associated with dMMR, not all tumors with a high TMB 
are actually associated with MSI-H, and future studies 
should address this aspect.
MSI and MMR, TMB, and PD-L1
The relationship between TMB, MSI, and PD-L1 has 
recently been explored in a broad range of cancer types 
(Fig. 1).10 There is some overlap of all 3 markers in a few 
cancers. However, in most cancers, overlap is infrequent or 
does not exist at all, and 69.5% of all cancer cases were neg-
ative for all 3 biomarkers (7890 of 11,348 tested). A popu-
lation of tumors exhibiting MSI-H status but low TMB 
and no PD-L1 expression was identified. Since MSI/
MMR status alone or in combination with PD-L1 positiv-
ity became an accepted predictive marker in the FDA in-
dication for checkpoint inhibitors, the finding that patients 
can test positively for only one of these markers obviously 
means that the number of patients now eligible to receive 
and hopefully benefit from checkpoint inhibition has been 
broadened. Until more is understood about how MSI, PD-
L1, and TMB work together and how this interaction is 
clinically relevant, the only reasonable option is to continue 
to assay for all 3 markers and ensure that the number of 
patients who are given the chance to benefit from these 
drugs is maximized.
Polybromo 1
PBRM1 is a non–MSI/PD-L1/TMB marker that could 
be predictive for response to checkpoint inhibitors. For 
example, clear cell renal cell carcinoma (ccRCC) responds 
to immune therapy but, unlike many other responsive 
human tumors, harbors a low burden of somatic muta-
tions. Even so, ccRCC has relatively high immune cyto-
lytic activity and a microenvironment with high immune 
and T-cell infiltration scores. In the past, large-scale 
sequencing studies demonstrated that PBRM1 loss of 
function (LOF) alterations are present in a large portion 
(up to 41%) of ccRCC tumors. Patients whose tumors had 
PBRM1 loss in both gene copies had significantly pro-
longed OS and PFS and manifested reduced tumor bur-
den in response to immune checkpoint therapy compared 
with patients without PBRM1 loss (log-rank P =  .0074 
and P = .029, respectively). Miao et al summarized that, 
given the high prevalence of PBRM1 LOF in ccRCC, this 
genetic mutation has important implications as a molecu-
lar tool for considering immune therapy responsiveness in 
ccRCC and possibly across other cancer types.142
The Role of HRD as an Emerging Biomarker
Repair of DNA double-strand breaks by cells is medi-
ated by the HR pathway or nonhomologous end-joining. 
HR is a complex DNA repair pathway involving multiple 
steps and has been reviewed extensively.143,144 The BRCA1 
and BRCA2 genes are critical for efficient double-strand 
DNA repair via HR and play an important role in the de-
velopment and clinical progression of many cancers.145,146  
FIGURE 1. Venn Diagram of the Relationships Between High Tumor Mutational Burden (TMB), High Microsatellite Instability (MSI-H), and High Programmed 
Death–Ligand 1 (PD-L1) for All Cancer Types.10
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If a cell carries BRCA1/BRCA2 LOF mutations, it loses the 
ability to repair double-strand breaks by HR and is termed 
the HRD pathway. Such HRD cells are highly sensitive 
to DNA-damaging agents, such as platinum-based chemo-
therapies and other cytotoxic agents that can cause DNA 
strand breaks.147,148 PARP plays a major role in DNA strand 
break repair. If PARP is inhibited, then cells ultimately die. 
Thus combining cytotoxic therapy with a PARP inhibitor 
can cause cell lethality.
Apart from mutations in the BRCA1 and BRCA2 genes, 
there are several other mechanisms associated with HRD. 
Defects in HR repair can be because of epigenetic changes 
such as BRCA1 promoter methylation, somatic mutations 
in key HR-related genes, and frequent copy number alter-
ations.149 In addition, mutations in other genes may result 
in HR-defective tumors and include but are not limited to 
PALB2, RAD51, CHEK2, and ATM.150-153
The most common approach to test for HRD is 
 genomic testing for alterations in BRCA1 and BRCA2 on 
the basis that BRCA1 and BRCA2 germline and somatic 
mutations are known to cause HRD. Testing for addi-
tional genes involved in DNA damage repair through HR 
can also be done through commercial resources. Several 
other approaches have been developed to measure tumor 
DNA repair function.154 The myChoice HRD test is an 
NGS assay that uses DNA extracted from formalin-fixed, 
paraffin-embedded or frozen tumor tissue. A tumor can 
be characterized as HR-deficient or HR-nondeficient by 
combining the HRD score that it generates and its BRCA1/
BRCA2 mutation status. HRD is defined as an HRD score 
≥42 or the presence of a mutation in BRCA1/BRCA2. As 
an example of its accuracy, the myChoice HRD assay was 
seen to identify 100% of BRCA-mutated tumors and 57% 
of non–BRCA-mutated tumors that had HR deficiencies 
in patients with platinum-sensitive, high-grade, serous or 
BRCA-mutated, recurrent ovarian cancer.65
The FoundationFocus CDx BRCA (Foundation 
Medicine, Inc) assay was used to detect both germline and 
somatic BRCA1/BRCA2 mutation types associated with 
response to PARP inhibitor therapy.155,156 This modified 
NGS-based assay determined the percentage of genomic 
loss of heterozygosity, mutations in BRCA1/BRCA2, and 
other HR genes in tumor tissue of patients with ovarian 
cancers taking part in the ARIEL PARP inhibitor rucapa-
rib trial. A prespecified cutoff of ≥14% for high loss of het-
erozygosity was determined. FoundationFocus CDx BRCA 
is the first FDA-approved companion diagnostic assay for 
rucaparib for the treatment of advanced ovarian cancer.
As we understand more about HRD in various cancer 
types, the indications for the use of PARP inhibitors will 
likely be broadened. Certain cancers, including ovarian, fal-
lopian tube, breast, primary peritoneal, and GI (specifically 
a subgroup of pancreatic adenocarcinomas and gastric/
esophageal cancers), have been shown to harbor  aberrations 
in genes involved in the HRD pathway. Mutations are seen 
not only in BRCA1 and BRCA2 but also in other relevant 
genes, such as RAD51, RAD54, DSS1, RPA1, NBN, ATR, 
ATM, CHK1, CHK2, FANCD2, FANCA, or FANCC.157,158 
Several PARP inhibitors have been FDA approved for the 
treatment of specific types of ovarian (olaparib, rucapa-
rib, and niraparib), fallopian tube (olaparib and niraparib), 
breast (olaparib), primary peritoneal (olaparib and nirapa-
rib), and pancreatic (olaparib) cancers, but not yet for other 
GI cancers. However, at present, HRD testing before 
PARP-inhibitor therapy is not necessary.
Other Hot Markers in Research
Although it is not by any means an exhaustive list, some 
exciting new biomarkers and their targeted therapies are 
discussed below.
NTRK and Entrectinib
Entrectinib (RXDX-101) was granted a breakthrough 
therapy designation by the FDA in 2017 for use as a treat-
ment for adult and pediatric patients with NTRK-positive, 
locally advanced or metastatic solid tumors who have either 
progressed after prior therapies or who have no acceptable 
standard therapy options (see also Neurotrophic receptor 
tyrosine kinase, above).27,28 A trial studying the treatment 
of patients with solid tumors (breast cancer, cholangiocar-
cinoma, CRC, head and neck neoplasms, melanoma, neu-
roendocrine tumors, NSCLC, ovarian cancer, pancreatic 
cancer, papillary thyroid cancer, primary brain tumors, 
renal cell carcinoma, and sarcomas) that harbor an NTRK1/
NTRK2/NTRK3, ROS1, or ALK fusion is ongoing 
(Clini calTr ials.gov identifier NCT02568267). In this trial, 
patients are assigned to different baskets according to tumor 
type and gene fusion. The primary outcome of the study 
will be the objective response rate to entrectinib.27
NTRK fusions may act as actionable targets in con-
junction with other potentially targetable alterations, 
such as PD-L1–positive or MSI-H status, meaning that 
therapeutic combinations (TRK inhibitors plus immune 
checkpoint inhibitors, for example) are a promising 
strategy.159
FGFR and Erdafitinib
The fibroblast growth factor receptor (FGFR) family 
comprises part of a tyrosine kinase signaling pathway that 
plays a role in oncogenesis through gene amplification, 
activating mutations, or translocation in several tumor 
types. Erdafitinib is an orally administered FGFR family 
tyrosine kinase inhibitor. Earlier this year, the FDA granted 
Breakthrough Therapy Designation for erdafitinib in the 
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treatment of urothelial cancer, which is based on data from 
a multicenter phase 2 clinical trial focused on evaluating the 
efficacy and safety of erdafitinib in the treatment of adult 
patients with locally advanced or metastatic urothelial cancer 
harboring specific FGFR mutations.160 The overall response 
rate was 42% in 59 patients for whom data were available.160 
Erdafitinib is also under investigation in the NCI-MATCH 
trial as a treatment for patients with tumors that have an 
FGFR mutation, fusion, or amplification (Table 7).
Also in the NCI-MATCH trial, 5 of 50 patients with an 
aberrant FGFR pathway had a partial response to AZD4547 
(another FGFR tyrosine kinase inhibitor).161 Two of these 
patient’s tumors had point mutations in FGFR2/FGFR3, 
and 2 others had FGFR3 fusions, suggesting that these par-
ticular types of mutation have increased sensitivity to the 
drug, which warrants further study in this patient subtype.
MET Amplification and MET Exon 14 and Crizotinib
Aberrant activation of MET receptor tyrosine kinase signal-
ing occurs in various cancer types as result of various MET 
alterations, including amplification and an exon 14 mutation. 
Crizotinib is an ALK/ROS1/MET inhibitor that is already 
FDA approved in ALK-positive or ROS1-positive NSCLC 
but also has proven clinical activity in cases of MET exon 14 
alterations and MET amplification. Preclinical studies have 
shown that inhibition of MET using crizotinib resulted 
in the inhibition of growth of cancer cells that possessed 
MET amplification both in vitro in cell lines and in vivo 
in preclinical models.162 In an updated phase 1 analysis of 
crizotinib in patients with low, medium, and high levels of 
MET amplification in advanced NSCLC, patients with high 
MET amplification showed clinically meaningful antitumor 
activity with rapid and durable responses. Crizotinib was 
generally well tolerated163 and is currently under study in 
the ASCO TAPUR trial for patients with tumors that have 
ALK, ROS1, or MET mutations and in the NCI-MATCH 
trial as a treatment for patients with tumors that have a 
MET amplification, MET exon 14 mutation, ALK translo-
cation, or ROS1 translocation or inversion (Table 7).
mTOR and Sapanisertib (TAK-228)
The mammalian target of rapamycin (mTOR) is a ki-
nase encoded in humans by MTOR. mTOR exists as a 
core component in 2 distinct multiple-protein complexes, 
TORC1 and TORC2. These complexes regulate several 
different cellular processes, including cell proliferation, 
cell motility, cell survival, protein synthesis, autophagy, 
and transcription. Sapanisertib (TAK-228) demonstrated 
a reasonable safety profile as well as promising prelimi-
nary antitumor activity in a range of tumor types with 
aberrant MTOR.164 Tuberous sclerosis complex 1 and 2 
(TSC1 and TSC2) mutations are also observed in cer-
tain tumor subtypes and may be targeted by sapanisertib. 
The agent is under investigation in the NCI-MATCH 
trial as a treatment for patients with tumors that have 
MTOR or TSC1/TSC2 mutations (Table 7).
PIK3CA and Taselisib
In the NCI-MATCH trial, 65 patients with a mutated 
phosphatidylinositol 3-kinase gene (PIK3CA) were treated 
with taselisib (a PIK3CA inhibitor) and, although there 
were no ORs to the drug, 24% of patients had prolonged 
stable disease for more than 6 months. Further research in 
selected cancer types is warranted.165
CDK4/CDK6 and Palbociclib
The cyclin-dependent kinases (CDKs) CDK4 and CDK6 
play a crucial role in the G1-S phase transition during 
cell cycling. Palbociclib, an inhibitor of aberrant CDK4/
CDK6, is FDA approved for the treatment of hormone 
receptor–positive, HER2-negative, advanced or meta-
static breast cancer in combination with an aromatase 
inhibitor as initial endocrine-based therapy in post-
menopausal women.166 Its effect on certain GI tumors 
is under investigation in the clinic.167 Palbociclib is also 
under investigation in the NCI-MATCH trial as a treat-
ment for patients with tumors that have CDK4 or CDK6 
amplification or CCND1, CCND2, or CCND3 amplifi-
cation (and Rb expression/protein in both study arms). 
The ASCO TAPUR trial is also investigating palboci-
clib in the treatment of patients with tumors that harbor 
CDKN2A, CDK4, or CDK6 amplifications (Table 7).
DDR2 and Dasatinib
DDR2 is a transmembrane receptor tyrosine kinase that 
plays a role in cancer progression by regulating the interac-
tions of tumor cells with their surrounding collagen matrix. 
DDR2 mutations are seen in several tumor types, includ-
ing lung cancer, breast cancer, brain cancer, gynecologic 
cancer, and prostate cancer.168 The multikinase inhibitor 
dasatinib blocks DDR2 kinase activity to various degrees 
and is under investigation in the treatment of patients with 
tumors that possess a DDR2 S768R, I638F, or L239R 
mutation (NCI-MATCH). The agent is also under inves-
tigation in the treatment of patients with tumors that har-
bor Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, or 
YES1 mutations (TAPUR trial) (Table 7).
Emerging Techniques
The Liquid Biopsy: Circulating Tumor Cells and 
Exosomes
Peripheral blood samples are a biomarker source by way of 
circulating tumor cells (DNA) and circulating nucleic acids 
or associated extracellular vesicles or exosomes.169-171 The 
use of liquid biopsy profiling has proven useful in selected 
clinical scenarios but, to date, despite its potential in the 
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management of patients with most metastatic solid tumors, 
this technique has not established a firm role in standard 
practice. Obvious advantages include ease of access to the 
tissue through a simple blood draw. An additional advan-
tage is that circulating samples may help reduce the prob-
lem of tumor heterogeneity as it ref lects the sum total of 
the tumor. However, when blood and tumor tissue are con-
currently collected and analyzed, results from circulating 
tumor cell analyses do not always match those obtained 
from tumor tissue analyses and thus are not always reliable.
Regarding extracellular vesicles or exosomes, a newly 
developed, minimally invasive ADAPT Biotargeting System 
characterizes complex biological systems in their inherent 
state(s) and relies on the fact that a large number of cells 
in the body secrete extracellular vesicles into the circulation, 
and the molecular composition of these “exosomes” correlates 
with the cell of origin. Through intercellular communica-
tion, exosomes play a part in controlling many tumor pro-
gressive processes, including immune evasion, angiogenesis, 
and metastasis.171 The ADAPT assay has been shown to 
have potential for biomarker identification and therapeutic 
use across most cancer types.171,172
Community Hospital Molecular Testing and 
Assessment Program
Because 85% of cancer care is delivered in a community 
setting, it is imperative that the programmatic decisions 
concerning molecular testing for cancer include stand-
ardization, physician engagement, and application to 
point of care. Hoag Hospital (a large community hospi-
tal in Newport Beach, California) decided to embark on 
an initiative within the context of precision oncology and 
identified the need for molecular testing. A committee of 
interested physicians (including molecular pathologists) 
and administrators was formed, and a request for proposal 
was developed and put to several CLIA-certified vendors 
to outsource genomic testing. Certain specific qualifica-
tions were emphasized, such as price point; turnaround 
time; results reporting and support structure; portfolio of 
testing, including NGS, CNV, and IHC for protein anal-
ysis and fusion genes (all preferably using disease-specific 
panels); and preauthorization and billing services. Several 
meetings were required to reach a final decision. Once 
the vendor was selected and contracting was optimized, 
all tumor molecular testing was standardized, and all 
ordering and tissue processing was sent through the cen-
tral pathology laboratory. It is important to note that this 
process had immediate benefit for the cancer programs 
because, before this arrangement, molecular testing was 
haphazard. Tumor tissue samples were being sent by 
individual physicians to multiple different laboratories/
vendors without standardization of tissue collection and 
processing, and subsequent result reports were generally 
faxed and unavailable when needed for valuable treatment 
assessment in the standard clinical or research settings.
After vetting and education concerning this new molec-
ular testing and assessment program at disease site commit-
tee and tumor board meetings, it was further decided that 
genomic testing would be reflexed and ordered by pathol-
ogy for selected clinical stages of solid tumors. The initial 
pilot project for this reflex testing was in NSCLC stages IB 
through IV. Before this initial pilot of genomic reflex testing 
in lung cancer, approximately 50% of the tumors in patients 
with advanced lung cancer were being tested for even the 
minimal NCCN guideline biomarkers. Now, over 95% of 
advanced lung cancers undergo genomic profiling evaluation 
that has resulted in pervasive use at the point of care. An 
illustrated example of this was a recent patient’s lung cancer 
demonstrating an actionable mutation in BRAF. The success 
of this pilot study in reflex profiling has expanded to other 
cancer disease sites, such as advanced head and neck cancers, 
ovarian cancers, glioblastoma multiforme, sarcoma, and rare 
tumors. Over the past 18  months, more than 300 tumors 
have undergone clinical grade genomic profiling, and those 
data are readily available to the treating physician through 
web access. Importantly, physician education is a key com-
ponent to the establishment of a comprehensive cancer mo-
lecular genomics program. Initiation of the more routine use 
of molecular markers and genomic profiling has stimulated 
interest and participation in the expanding clinical appli-
cations. Along with the assistance of molecular pathology, 
presentation of genomic data is now frequently requested, 
and this provides points of discussion in the cancer disease 
site tumor board meetings. In addition, this information has 
led to optimal patient selection and a definitive increase in 
referrals to the phase 1 clinical trials program.
Despite the successful implementation of this intu-
itional program in cancer molecular testing, challenges 
remain. These fall into several categories, such as reim-
bursement issues, evaluating the tumor genomic data for 
potential germline testing, paring results to clinical trial 
opportunities, and collecting and collating the genomic 
data to clinical information and outcomes, as well as the 
incorporation of new opportunities such as sequencing 
cell-free DNA or routine pharmacogenetic testing. The 
overall goal of this program was to provide added value 
and physician engagement in precision oncology. This is 
now a work in progress, but we are already evaluating the 
growth opportunity to enhanced patient care.
Challenges and Open Questions in Molecular 
Profiling
Absence of Randomized, Controlled Clinical Trials
One of the major challenges with the use of large panels 
or whole genome sequencing is the absence of randomized 
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clinical trials demonstrating benefit. Although some ret-
rospective analyses have appeared promising, in general, 
the field demands more evidence given the expense of 
drugs and genomic tests and potential harm from expos-
ing patients to toxicity of drugs without proof of efficacy. 
A properly performed randomized clinical trial requires a 
large number of patients and needs to be a national study 
requiring significant resources to cover costs of testing, 
cost of drugs, and data analysis. It would be problematic 
to randomize patients to genomic profiling versus no test-
ing. It is also complicated to compare standard therapy 
with molecularly assigned therapy in terms of comparing 
apples to apples and defining what the valid endpoints 
should be. It is clear that the gold standard is OS, but 
this may be affected by multiple lines of therapy and 
ultimate use of targeted therapy beyond a particular study. 
PFS is a reasonable endpoint but, if the randomization 
occurs at a time when there is effective standard therapy, 
then the impact of molecularly targeted therapy may be 
underestimated. With the era of precision oncology, there 
is opportunity to break new ground in trial design. In 
this regard, pooling N-of-one data that account for other 
factors described below, such as tumor heterogeneity, may 
allow for useful evidence to help patients even if it does 
not rise to randomization. In addition, the PFS ratio as 
defined by Von Hoff remains a good metric to determine 
benefit of molecularly assigned therapy.
Lack of Drugs
Another major challenge is the lack of availability of drugs 
for numerous drivers of various cancers. Examples of major 
drivers for which there are currently no approved drugs in-
clude mutated β-catenin, mutated P53, or mutated RAS, 
among others. On the optimistic side, as drugs are discov-
ered and developed, they can be offered retrospectively to 
patients who have actionable mutations. A related issue is 
the lack of drugs that effectively target emergent resist-
ance mechanisms. There are some exceptions with mutated 
EGFR, ALK, or BCR-ABL.
Tumor Heterogeneity
It is clear that advanced cancers, especially those that 
have been treated, harbor significant tumor heterogene-
ity. This includes intralesion heterogeneity, interlesion 
heterogeneity, and interpatient heterogeneity, all of which 
complicate treatment recommendations and outcomes of 
studies.
Platform Heterogeneity
In clinical practice, there are several different avail-
able platforms for molecular profiling; each test has its 
own sensitivity and specificity. The scope of the testing 
varies in the number of genes, whether RNA or protein 
expression is assessed, and whether actionable fusions are 
readily detectable. Such heterogeneity makes it difficult 
to pool data from different platforms. The various com-
mercial platforms or those performed within academic in-
stitutions are continuously evolving, further complicating 
the issue of platform heterogeneity. Thus older platforms 
that did not capture actionable targets for which there are 
effective therapies lead to data sets that may underesti-
mate the value of genomic testing with respect to patient 
outcomes. Moreover, no study to date has shown that 
larger panels are worth doing over smaller targeted gene 
panels that are part of standard of care (eg, KRAS, NRAS, 
BRAF, and MSI in CRC). However, it is not unreason-
able to expect that the many genomic changes represent-
ing the tail end of the curve of drivers may affect patient 
outcomes, especially if there are available drugs that tar-
get their pathways. With the emergence and popularity 
of liquid biopsy, this yet further adds complexity to the 
platforms. Of note, in the TAPUR study, which mod-
els real-life situations, liquid biopsy is acceptable for the 
identification of actionable targets to allow enrollment in 
a treatment arm.
CLIA-approved laboratories offering molecular panel 
analysis
Before a patient sample of any kind can be tested, the assay 
in question must be validated in a CLIA-certified labora-
tory. CLIA defines a clinical laboratory as any facility that 
performs laboratory testing on specimens derived from 
humans for the purpose of providing information for the 
 diagnosis, prevention, or treatment of a disease or im-
pairment. The CMS regulates all laboratory testing per-
formed on humans in the United States through the CLIA 
program. In total, CLIA covers approximately 260,000 
laboratory entities. The Division of Clinical Laboratory 
Improvement and Quality, within the Quality, Safety, and 
Oversight Group under the Center for Clinical Standards 
and Quality, has responsibility for implementing the CLIA 
program. The objective of the CLIA program is to ensure 
quality laboratory testing. Although all clinical laboratories 
must be properly certified to receive Medicare or Medicaid 
payments, CLIA has no direct Medicare or Medicaid pro-
gram responsibilities.
Clinical laboratories must constantly evolve their test of-
ferings to support the most recent advances in cancer care. 
For NGS tumor profiling assays, there are multiple com-
mercially available kits with similar claims for gene con-
tent and sensitivity. Many factors contribute to the decision 
of which assays or customized solutions will best meet the 
needs of the laboratory, clinicians, and patient population. 
Kit costs, capital equipment expenditures, complexity of 
workflow, and turnaround time are all important factors 
that can be relatively easily compared and assessed between 
CA CANCER J CLIN 2019;69:305–343
337VOLUME 69 | NUMBER 4 | JULY/AUGUST 2019
assay systems. However, the more important parameters for 
determining effective, personalized treatment for patients 
are accuracy, reproducibility, and sensitivity of the assay, 
and these can be much more challenging to critically eval-
uate but must be rigorously validated.173-176 The use of a 
highly multiplexed, consistent, and well-characterized ref-
erence material greatly facilitates the comparison of assay 
systems.177
Data Sharing
Given the numerous challenges described above and oth-
ers, including limitations of electronic medical records, 
issues with intellectual property, commercial interests, 
Health Insurance Portability and Accountability Act of 
1996 (HIPAA) regulations, and quality of clinical out-
comes data, there are major difficulties with data sharing to 
 expand data sets through larger sample size. In this regard, 
the Caris Precision Oncology Alliance has been addressing 
some of the issues through the CODE database, which is 
increasing the number of patients for whom analysis of clin-
ical outcomes is possible as a function of clinical, genomic, 
or drug use. Other initiatives of national prominence in-
clude Orion, Project GENIE, the WIN Consortium, 
the Precision Medicine Exchange Consortium, and the 
Memorial Sloan Kettering (MSK) Cancer Alliance.
Timing
The ideal time to perform genomic testing to maximize 
its therapeutic value to individual patients with cancer re-
mains a matter of controversy, and the evidence base on 
which to make recommendations is still evolving. Initially, 
physicians mainly ordered testing in patients with ad-
vanced disease who had exhausted standard-of-care treat-
ment options to help inform choices for treatment with 
experimental agents. Trials are now underway in groups 
of patients with earlier stages of disease. For example, 
the newly activated, NCI-sponsored intergroup stage III 
colon cancer adjuvant therapy trial randomizes patients to 
standard adjuvant therapy with FOLFOX or FOLFOX 
plus experimental treatment with a PD-1 inhibitor. Only 
patients with MSI-H, stage III colon cancer will be eli-
gible for randomization, and the eligibility  determination 
mandates genomic testing for defective MMR in  patients 
with localized disease. Commercial genomic testing now 
includes MSI testing in addition to a battery of genes 
relevant to tumor progression. The addition of MSI 
testing to these panels is a consequence of the recent 
approval of pembrolizumab and nivolumab. The agents 
are currently approved for the treatment of refractory 
tumors of any histology that exhibit defective MMR.141 
In patients with advanced cancers, it is clear that the 
tumor genome continues to evolve with time and with 
the pressure exerted on cells by treatments that selectively 
favor the growth of treatment-resistant subclones.178 
Investigators remain concerned about clonal evolution 
and often will recommend rebiopsy of tumors when pa-
tients have refractory disease to ensure that the genomic 
analysis used to make informed decisions about clinical 
trials with targeted agents is ref lective of the  tumor’s cur-
rent biology.179 Others suggest testing at the first sign of 
advanced disease, as the efficacy of conventional chemo-
therapy is variable and strategies for salvage therapy may 
be required sooner rather than later. The use of “liquid 
biopsies” either on circulating tumor cells or on cell-free 
DNA has been touted as a method of assessing the tumor 
genome without the need for a repeat, invasive biopsy. 
This remains a research tool at this time and is not gen-
erally a part of clinical practice. Continued data analy-
ses are urgently needed and will inevitably occur as more 
samples are tested and the practical application of these 
assessments are translated into treatment decisions.
Discussion
In 2019, optimum cancer care requires state-of-the-art 
molecular diagnostics, a solid knowledge base to interpret 
and apply the results, and a nearly constant awareness of 
changes on the horizon. The field is moving that quickly. 
Comprehensive testing performed on our patients at the 
beginning of 2019 is likely to be incomplete today. Drug 
approvals are no longer based solely on large phase 3 tri-
als; these late-stage trials are being replaced by “basket” and 
“umbrella” trials, allowing us to ensure that the right drug is 
given to the right patient faster. Subsequent new regulatory 
and payer approvals seem to come daily. Precision medi-
cine is now a part of our standard practice, but with this 
comes many new challenges. How do we deal with tumor 
heterogeneity, and will liquid biopsies satisfactorily replace 
tissue-based testing? Are we justified in, and can we afford, 
testing a large sample of patients, knowing that we will only 
rarely find the sought after “needle in the haystack?” How 
do we manage our patients’ expectations when there is so 
much press and hype surrounding our new discoveries? Can 
we afford to develop and ultimately to pay for increasingly 
expensive therapies targeting increasingly smaller propor-
tions of patients? There is, of course, no turning back, but 
there is much work ahead. ■
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